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Abstract 
Off-label Prescribing: Pediatrician Beliefs and Experience 
Elizabeth Evola, BE, MS 
I 
1 
Seton Hall University 
I 2012 
J 
I Chair: Dr. Genevieve Pinto-Zipp 
I 
t 
I When a health authority approves a drug for marketing, they approve the 1 
I 
drug for use in the population tested by drug manufacturer. However, once the I drug is on the market, a physician may legally prescribe the drug in whatever 
manner they feel is appropriate for their patients. When the drug is prescribed in 
a manner outside of the marketing approval, it is prescribed in an off-label 
manner. Off-label prescribing is prevalent in many populations, including up to 
80% of the drug prescribed to children. 
The purpose of this study was to determine the beliefs and experience of 
pediatricians toward this practice. A total of 167 pediatricians answered an 11 
question survey regarding their beliefs and experience with off-label prescribing. 
The results indicated that pediatricians are concerned with the safety and 
efficacy of drugs that are prescribed in an off-label manner and they believe that 
more references should be available to determine the best medicines to 
prescribe to their patients. In addition. respondents are concerned about the 
13 
legal liabilities, patient complaints, and insurance coverage related to off-label 
prescribing. 
As this study is the first to determine the beliefs and experience of 
pediatricians toward off-label prescribing, the results provide a foundation for 
pediatricians to develop effective guidance and improve their clinical judgment 
when prescribing medicines off-label. 
14 
Chapter I 
Introduction 
Background of the Problem 
Prior to marketing a medicine to a specific population, pharmaceutical 
manufacturers must submit evidence to a regulatory health authority indicating 
that the medicine is both safe and effective for that population. The evidence 
required by the health authority includes data from tests in humans, which are 
collectively known as clinical trials. If the results from the clinical trials indicate 
that the benefits of the medicine outweigh the risks, the regulatory authority 
generally approves the medicine for the specific indication, population, route of 
administration and dosage studied in the clinical trial. However, once the 
medicine is approved for a single indication, population, route of administration 
and dosage, any physician may legally choose to prescribe the drug in a manner 
not approved by the regulatory authority (Cohen, 1997). 
When a medical practitioner prescribes a drug for an indication, dose, 
population or route of administration not indicated on the drug's label (I.e. in a 
manner not approved by a regulatory authority), they have prescribed the drug in 
an "off-label" manner. Many people believe that because medicines prescribed 
j 
1 
i 
I 15 
I off-label are not tested in a clinical trial that the patients may be at a higher risk 
I 
for safety concerns or that the medicine may not be effective for the prescribed 
use (Cohen, 1997). J 
! 	 There is some research that indicates that even though they prescribe 
I 	 medicines off-label, some physicians may not be aware of the practice of off-
label prescribing. For example, the results of one study indicate that about 1 in 4 
I 
~ physicians were not familiar with off-label prescribing, and that only 40% of 
physicians knowingly prescribed medicines off-label (Ekins-Daukes, Helms, 
Taylor & McLay (2005)). This lack of off-label prescribing practices combined 
with the fact that many medications may not have sufficient evidence to support
I 
! 	 its usage in the manner it was prescribed, could limit health care management
I 
i 	 options and or put patients at increased risk for adverse effects resulting from the 
I 
management practices implemented. 
Additional risks exist when the patient receiving the off-label medicine is a 
I child because children have more active physiological changes than adults 
I j 	 (Cohen, 1997). However, up to 80% of medicines prescribed to children are off-
t 
1 	 label (Pandolfini & Bonati, 2005; Shah, et aI., 2007). Although there are no 
I 
I 
j 
studies that indicate exactly why off-label prescribing is so prevalent in this 
population, Conroy (2002) argues that the pediatricians who are aware of the 
practice and knowingly prescribe medicines off-label may do so because 
! information on the proper use of the medicine is not available. O'Reilly & Dalal 
I 
4 (2003) further suggest that a pediatrician may prescribe a medicine off-label 
because there is a lack of adequate information regarding the appropriate use, j 
! 
I 
J 
J 
1 	 16 
f 
.1 
I 	 safety and efficacy of the medicine, a medical practitioner's fear of litigation if the 
medicine they prescribe is not approved for the use prescribed, whether the 1 
I 
~ 
patient has insurance coverage for the preferred medicine or whether a patient 
I has complaints regarding the use of off-label medicines to treat their disease. 
The information is not available because, often, drug manufacturers do not 
perform clinical trials in a certain population, such as children, because the cost 
of performing the research outweighs the potential marketing value - the 
pediatric population is relatively small compared to the adult population for most 
diseases. To encourage drug manufacturers to perform clinical trials in the 
pediatric population, in 1997, the FDA enacted the pediatric exclusivity program. 
This program allowed the FDA to grant an extra six months of patent rights to 
companies that performed clinical trials in children. For many medicines, an 
extra six months of patent exclusivity could mean up to half a billion dollars in 
additional sales of the medicine and more than cover the cost of the research. 
While the purpose of this program was to encourage pharmaceutical 
companies to perform more clinical trials in children, thus enabling physicians to 
have more information on how to prescribe the medicine in the pediatric 
population. While the program incentives successfully encouraged 
pharmaceutical manufacturers to perform over 250 additional studies in children 
between 1998 and 2004, there was no incentive for the manufacturer to publish 
the study results. Benjamin, et al. (2006) found that the clinical trial results were 
published in peer-reviewed journals less than half of the time. Thus the lack of 
published results restricts the establishment of evidence-based practice. Often, 
17 
the drug studied may have been on the market for a while and the manufacturers 
may not believe that publication was a worthwhile investment of resources. 
Therefore, any negative results or results that are not published or do not lead to 
a change in the drug's label, may never reach the physician prescribing the 
medicine to determine the appropriate use of the medicine for their patient 
(Benjamin, et al. 2006). 
Unfortunately, even if proper pediatric prescribing information is available, 
it may not be present in the medical drug references most often utilized by 
physicians. Therefore, physicians may not be aware of the proper current use of 
a medicine. For example, greater than 70% of the entries in the Physicians Desk 
Reference (PDR), a popular reference used in the United States, have either no 
pediatric dosing information or an explicit statement saying that safety and 
efficacy in children has not been determined (Blumer, 1999). Moreover, the 
results of a survey given to 500 family physicians in Canada indicated that the 
reference used by 87% of the physicians, the Compendium of Pharmaceuticals 
and Specialities, did not reflect the current pediatric standard of care (Matsui, 
Jardine, Steer, Cukernik & Rieder (2003)). 
Another concern with off-label prescribing is insurance coverage. Many 
prescription benefit companies will reimburse patients only for drugs that have 
been approved by the FDA for the use in which they were prescribed (O'Reilly & 
Dalal, 2003). In situations where off-label treatments may be more effective than 
approved drugs, reimbursement issues can hinder a physician's ability to 
effectively treat a patient. Patients in these situations may be forced to pay out­
18 
of-pocket for their drugs or be treated with drugs that may be less effective for 
their situation. 
Accordingly, physicians also fear litigation when prescribing a medicine 
off-label (Hill, 2005; O'Reilly & Dalal, 2003). Although off-label prescribing is 
legal, physicians must use their professional judgment, based on the scientific 
literature and their personal experience, when choosing to prescribe a medicine 
in an off-label manner. If a physician is sued for prescribing a medicine off-label, 
it is his/her responsibility to prove that prescribing the-medicine was most 
appropriate choice for their patient. Some commonly used references may not 
have the complete prescribing information for a medicine so proving proper use 
of the medicine may be difficult. Therefore, even if a physician believes that an 
off-label medicine may be more appropriate for their patient, they may fear 
litigation and possibly withhold a better treatment from their patient (O'Reilly & 
Dalal, 2003). 
Physicians also want to please their patients when prescribing medicines. 
Lowe-Ponsford & Baldwin (2000) surveyed 200 psychiatrists to determine how 
common off-label prescribing was in their specialty and to ascertain whether or 
not they felt sufficient prescribing guidelines were available. Although 65% of 
respondents had prescribed medicine off-label in the last month, only four 
percent had received complaints from their patients regarding the off-label 
prescribing. The respondents did not indicate the context of the specific 
complaints but the authors believe that, based on respondent comments, 
19 
whether a patient complains about the use of a drug off-label may be another 
factor that influences physicians to prescribe a medicine off-label. 
Most importantly, previous studies report that off-label treatments can lead 
to a higher incidence of adverse drug reactions (ADRs). Turner, Nunn, Fielding, 
and Choonara (1999) found that patients who were prescribed a drug off-label 
had a 1.5 times greater chance of an ADR than those who were prescribed drugs 
! according to their marketing license. Choonara and Conroy (2002) argue that 
1 
I because children have a significantly different physiologic and metabolic makeup than adults, medicines may severely affect their physical and metabolic status. 
1 
1 In fact, the results of a survey of 257 hospital-based pediatricians indicated that ~ 
I about half of pediatricians were concerned about efficacy and safety of off-label 
medicines (McLay, Tanaka, Ekins-Daukes & Helms (2006». Therefore, patient 
1 j safety concerns in the pediatric population are paramount. 
Purpose of this Study 
Because the physician ultimately decides what medicine to offer what 
patient, it is important that their perspectives of off-label prescribing practices are 
understood. This is especially important in the treatment of children, whose 
maturing bodies may be more sensitive to the medicine's effects. The results 
from this study will provide an understanding of factors that influence a 
pediatrician's decision to prescribe a medicine off-label and thus may lead to 
strategies for promoting more informed off-label practices amongst pediatricians. 
Research Question 
20 
What factors influence a pediatrician's decision to prescribe medicines off­
label? 
Hypotheses 
• 	 Pediatricians will report that the primary factors that influence their 
decision whether or not to prescribe a medicine off-label are: 
o 	 lack of appropriate references 
o 	 concerns about patient safety. 
• 	 Pediatricians will report that the secondary factors that influence their 
decision whether or not to prescribe a medicine off-,Iabel are: 
o 	 legal concerns 
o 	 insurance coverage 
o 	 patient complaints. 
21 
Chapter II 
Review of Literature 
A license to market a medicine in the United States is given to a 
pharmaceutical manufacturer only after they provide sufficient data to the FDA 
that the medicine is safe and effective for a particular use in humans. The 
process for gathering these data to submit to the FDA is outlined in the first 
section of this literature review. 
Once the product license is granted by the FDA to the manufacturer, 
physicians may legally prescribe the medicine in any manner, whether or not it is 
indicated on the product license. If the medicine is prescribed outside of its 
product license, it is prescribed in an off-label manner. The second section of this 
literature review describes the prevalence of off-label prescribing in many 
populations, including children, the target population of this study. 
Although off-label prescribing is, in many cases, the standard of care for 
some patients and diseases, there are risks associated with the practice, 
especially for the pediatric population. The third portion of the literature review 
describes these concerns and risks from both the patient and physician point of 
view. 
22 
The final portion of this literature review explains the FDA efforts to 
encourage pharmaceutical manufacturers to collect data about the use of their 
medicines in children with hopes that the additional data collected from these 
studies can allow physicians to make more informed decisions about the use of 
the medicine in this population. 
The Drug Development and Approval Process 
When a drug manufacturer develops a new medicine, it must be approved 
by the FDA prior to marketing in the United States. FDA approval is given only 
when a manufacturer can prove that the benefits of the drug outweigh the risks 
and that the drug is safe and effective for human use. In order to determine the 
safety and efficacy of a drug, a drug manufacturer must perform several tests 
using the drug. The results of these tests allow the FDA to determine whether or 
not the drug should be approved for use. Blumer (1999) and Kaitin & Healy 
(2000) describe how the typical drug development process encompasses several 
unique steps: pre-clinical testing, clinical testing, approval and post-marketing. 
Figure 1, which is based on their research, summarizes the cost, time and 
resources required for each step of the drug development process and how the 
steps relate to one another. 
Pre-clinical testing. Once a chemical entity that has some beneficial 
effects on a disease target is discovered, a drug manufacturer performs pre-
clinical tests using the molecule. These tests, which usually last between 3 and 
6 years, are performed using various laboratory and animal models and their 
purpose is to determine initial safety and efficacy profiles of the medicine. 
23 
Clinical testing. If the results from the pre-clinical tests indicate that the 
medicine is safe and effective, a drug manufacturer may apply for an FDA 
Investigational New Drug Application (IND). Approval of the IND allows the 
manufacturer to begin clinical trials. There are three phases of clinical trials 
during the clinical testing portion of the drug development process. The three 
phases together can last from 2-6 years. 
Phase I clinical trials. The first time the medicine is tested in humans is 
during phase I clinical trials. The purpose of phase I clinical trials are to 
determine the safety, pharmacokinetics and pharmacodynamics profiles of the 
medicine. Therefore, the participants in these trials are healthy volunteers and 
not patients who need the medicine for therapy. Typically 20-100 participants 
are involved in phase I trials. 
Phase /I clinical trials. The first time the medicine is tested in patients 
who have the disease to be treated is during Phase II clinical trials. The primary 
purpose of phase II trials is to determine the efficacy profile of the medicine. 
Dosing, kinetics and metabolism of the medicine are further studied in these 
trials. Typically, 100-500 patients are enrolled in these studies. 
Phase 11/ clinical trials. The purpose of phase III clinical trials is to 
further evaluate the safety and efficacy of the medicine in patients with the 
disease to be treated. Phase III clinical trials involve many more participants 
than in the previous two phases, typically 1,000 to 5,000 patients. 
New Drug Application and approval process. Once the manufacturer 
has enough data to support marketing the medicine, they must submit a New 
24 
Drug Application (NDA) to the FDA. The NDA contains the data gathered from 
both the preclinical and clinical tests performed. The FDA takes an average of 
1.4 years to grant approval to the manufacturer. Once the medicine is approved 
by the FDA, the manufacturer can legally market the medicine in the United 
States, but only for the population(s) and indication(s) tested in clinical trials with 
positive results. 
Post marketing (Phase IV clinical trials). As clinical trials are 
performed over a specific and relatively short duration with a relatively small 
population, the safety and efficacy profiles of the medicine may not be fully 
known at the time the medicine is approved. Once a medicine is on the market, 
a manufacturer may choose to (and sometimes may be forced to by the FDA) 
perform phase IV clinical trials to further evaluate the medicine for the already 
approved use or new uses once it is on the market. The results of these clinical 
trials are often used to expand the information on the original label, with FDA 
approval. 
25 
Figure 1. The steps of the typical drug development process, their 
relationship to one another, their purpose, and the average time, cost and 
patients required for each step. 
I 

PRE-CLINICAL TESTING 
~ - Food and Drug Adrrinistration 
-Drug Discovery If\[) - ~vestigational New Drug Application 
CLINICAL TES1·ING NJA - New Drug Application
-Animal Testing 
Phase I: 

20-100 healthy volunteers 

AJrpose: initial safety, biological effe~c~_ 

rretabolism, kinetics 

Phase II: 

100-500 patient volunteers 
 POST MARKETING 
________ ',",DIIi8"AJrpose: efficacy, dosing, kinetics, Phase IV: ~4Ict.rretabolism 
_ Patients given drug for 'or .Phase III: therapy 
I 
~ I1000-5000 patient volunteers AJrpose: safety and efficacy AJrpose: adverse 1 ,.act'm,. pattem,.
additional indications
13-6 years 2-6 years Awrage 1.4 years . 
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Prevalence of Off·label Prescribing 
A medicine is prescribed off-label when it is prescribed outside of its 
product license with respect to the dosage, age, indication and/or route of 
administration. Determining the prevalence of off-label prescribing can be 
difficult for a researcher because all of these factors may not be known to the 
researcher at the time of the study. For example, a researcher may be able to 
easily determine if the dosage was prescribed according to the product label by 
comparing the label to the dosage given, but it may be difficult, due to privacy 
laws, for a researcher to determine the age or indication of the patient who 
received the medicine. 
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Studies conducted in various populations determined that medicines are 
prescribed off-label 20-90% of the time. The majority of these studies reviewed 
only one or two conditions for determining whether or not a medicine was 
prescribed off-label (e.g. only indication or only patient age or both). In addition, 
the literature suggests that the greatest prevalence of medicines prescribed off-
label is to patients in the hospital and to children with serious or rare diseases 
(O'Reilly & Dalal, 2003). 
Patient location. When comparing the prevalence of off-label prescribing 
between in-patients and out-patients, research suggests that the lowest 
percentage of off-label prescribing occurs in the outpatient setting. Radley, 
Finkelstein and Stafford (2006) performed a retrospective analysis of United 
States prescribing data to determine the rate of off-label prescribing among 
office-based physicians. The researchers reviewed prescription data from the 
I National Disease and Therapeutic Index (NDTI), a national survey that requires 
office-based physicians to report all diagnoses and drug therapies for every 1 
patient encounter during two randomly selected consecutive workdays. Of the j total of 725 million prescriptions analyzed, the authors found that 21 % (150 
I 
million) were prescribed off-label due to the indication they were used to treat. In 
addition, the authors determined that out of the 150 million prescriptions, only 
I 27% had strong scientific support for the use in which they were prescribed. j 
On the other hand, in the largest study of off-label prescribing in the 
United States pediatric population to date, Shah, et al. (2007) reviewed 
prescriptions from a database containing demographic information, diagnoses 
27 
and procedures for all patients discharged from 31 pediatric hospitals in the 
United States. In order to determine the prevalence of off-label prescribing, the 
authors compared the patient's age with the FDA approved age range for any 
indication of the medicine. Out of a total of 355,409 patients, 297,592 (78.7%) 
received at least one medicine off-label indicating that off-label prescribing is 
especially prevalent in the pediatric inpatient population. 
Patient diagnosis. The prevalence of off-label prescribing can vary due 
to the patient's disease, regardless of their age. Sugarman, Fletcher and 
Feldman (2002) reviewed 7 years of data from a United States National Center 
for Heath Statistics survey to determine the prevalence of off-label prescribing for 
dermatologic diseases in adults. For approximately 200 million office visits 
where the primary and only diagnosis was dermatologic, the researchers 
compared the patient's diagnosis to the medication prescribed to determine 
whether the medicine was prescribed off-label. Depending on the diagnosis, up 
to 73% of prescriptions were prescribed off-label. 
Loder and Biondi (2004) prospectively studied off-label prevalence rates in 
an adult specialty headache practice in the United States over a 30-day period. 
During the study, physicians were instructed to record the medication(s) 
prescribed and whether they were prescribed according to the FDA-approved 
package insert. In total, 379 eligible prescriptions were written during the study 
period and 178 (47%) were prescribed off-label. 
Researchers report similar results regarding the prevalence of off-label 
prescribing in different diseases in the pediatric population as well. Johnson and 
28 
Clark (2001) performed a prospective study of medicines prescribed by child and 
adolescent mental health practitioners in England over a six month period. When 
prescribing a new medicine to their patient during the study period, the 
prescribing clinician recorded the age of the child, the drug prescribed, the 
maximum dosage prescribed and the condition being treated. Out of the 478 
new medicines prescribed during the study period, 39% were prescribed off-
label. 
Conroy, Newman and Gudka (2003) also prospectively studied pediatric 
off-label drug use in the United Kingdom. However, they reviewed prescription 
data for pediatric oncology inpatients and outpatients of a medical center during 
a 4 week period. During the study period, the researchers collected the 
patient's hospital number, age, weight, surface area, diagnosis, drugs 
administered, formulation, date and route of administration, dose, frequency and 
indication for use. Although they collected more data on their patients than 
Johnson and Clark (2001), which would allow them to determine that a medicine 
was prescribed off-label for more reasons (e.g. route of administration) they 
found that only 26% of the medicines prescribed were off-label. 
Lastly, 't Jong, Eland, Sturkenboom, van den Anker and Stricker (2004) 
retrospectively reviewed a random sample of patient data 'From a database of 
prescription data from a group of 150 general practitioners in The Netherlands to 
determine the prevalence of off-label prescribing of respiratory drugs given to 
children during a one year period .. The data reviewed included the name of the 
medicine, dosage, indication and patient age. Of the of 5,253 respiratory drugs 
29 
issued to 2,502 patients during the study period, only 20.3% were off-label, even 
less than the prevalence found in the Conroy et al. and Johnson and Clark 
studies. 
The results of each study reviewed vary significantly because the authors 
of each study used different methods for determining whether a medicine was 
prescribed off-label. Also, the duration of the study, whether it was retrospective 
or prospective, the location of the physicians, and the specific disease studied 
explain the variance as well. In any case, these studies indicate that off-label 
prescribing is prevalent in a variety of geographic locations (United States, 
United Kingdom, and The Netherlands), indications (dermatology, headache, 
mental health, oncology, and respiratory diseases) and patient populations 
(adults and children). 
Patient age. The prevalence of off-label prescribing can also vary 
depending on the age of the child. Schirm, Tobi, & de Jong-van den Berg (2003) 
analyzed the outpatient pharmacy records for over 19,000 children aged 16 and 
younger in the Netherlands to determine the age of children most likely to receive 
a medicine off-label. The authors first compared the medicine's label to the age 
of the child to determine if the child was at least the minimum age for use and 
then they grouped the results by age (0-1, 2-5, 6-11, and 12-16 years) to 
determine the proportions of off-label prescribing per each group. In a total of 
66,222 prescriptions, 20.6% were prescribed off-label and children aged 12-16 
years old received the greatest percentage of medicines off-label (27.4%) and 
children aged 2-5 received the least percentage of medicines off-label (16.4%). 
30 
Conversely, Conroy, Mcintyre & Choonara (1999) determined that off label 
drug use is more prevalent in neonates than any other age group. These authors 
prospectively collected patient demographic data, diagnosis, and prescription 
information for all patients admitted to a neonatal intensive care unit in the United 
Kingdom over a 13 week period. In order to determine whether the medicine if 
the medicine was prescribed off-label, the researchers compared the patient age, 
dose, indication and route of administration to several drug reference sources. 
Of a total of 455 prescriptions issued during the study period, 249 (54.7%) were 
prescribed in an off-label manner and many were off-label for more than one 
reason. 
Limitation of prevalence studies. Although varied, the results of studies 
described in this section indicate that off-label prescribing is prevalent across 
many diagnoses, patient populations, and locations. The variance is at least 
partially due to the methods followed during the study to determine the 
prevalence of off-label prescribing. For example, some researchers only have 
access to the patient age and name of medicine prescribed (e.g. Schirm et aI., 
2003). In this case, if the medication was prescribed off-label because the 
dosage did not match the dosage information on the product license, its use 
would not be considered off-label. Because of this limitation, the results of most 
of the studies presented in this section likely underestimate the magnitude of off-
label drug use. 
Concerns of Off-label Prescribing 
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While off-label prescribing is legal, it is important for patients and 
physicians to understand all the risks and benefits of the practice. The following 
section outlines the concerns identified in the literature regarding this practice. 
Physician knowledge. According to the FDA, physicians are required to 
be well informed about the proper use of a medicine and prescribe it only when 
the use is based on "firm scientific rationale or on sound medical evidence" 
t (http://www.fda.gov/oc/ohrtlirbs/offlabel.html. Accessed March 18,2007). Drug 
t prescribing manuals, pharmacies, the FDA, and pharmaceutical companies are 
all commonly used sources of information regarding the proper use of a1 
medicine. However, according to Blumer (1999), the Physicians Desk Reference 
(PDR), which is the most recognized information source for practitioners in the 
United States, is not the best reference. The PDR contains only the drug's 
package insert, or label. It does not contain any information on off-label uses, or 
in-depth information regarding the safety or tolerance of a medicine. More 
specifically, the PDR contains either no pediatric dosing information or explicitly 
states that the safety and efficacy of the medicine in children have not been 
determined. Therefore, a physician may have difficulty being well informed about 
the proper use of a medicine and ensuring the use is based on sound medical 
evidence. 
Ekins-Daukes, et al. (2005) prospectively surveyed 346 doctors in 80 
outpatient practices in Scotland to determine their attitudes and experience with 
off-label prescribing to children. Of the 202 (58%) surveys returned, over 70% 
indicated that the doctors are familiar with off-label prescribing and 40% 
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knowingly prescribe off-label. These results indicate that there are still many 
physicians that are not aware of the practice. Interestingly, almost all doctors 
surveyed indicated that development of pediatric formulations and clearer 
dosage information were the best means to reducing off-label prescribing 
indicating that they believe that the current references are not complete. 
Lastly, Radley, et al. (2006) analyzed prescription data from the 2001 
National Disease and Therapeutic Index (NDTI), a quarterly survey of about 
3,500 US office-based physicians regarding their clinical activity. The authors 
I 
1 
studied the prescribing patterns of the NDTI top 100 prescribed medicines as 
I 
 well as 60 additionally randomly selected medications. Using the patient's 

diagnosis, they categorized the prescriptions as prescribed according to the FDA 
1 
approved label, off-label with strong scientific support, or off-label with limited or 
no scientific support. They found that of the 575 million prescriptions in theI j studied sample, 150 million (21 %) were prescribed off-label and 109 million 
I 
j 
(73%) medicines prescribed off-label had little or no scientific support. 
I The results of these studies indicate that although physicians are required 
I to prescribe medicines based on their knowledge and expertise, they may not I 
I always have adequate information to assist them when prescribing a medicine. If 
I physicians cannot rely on approved and published information to make proper 
prescribing decisions, then they may subject their patients to unnecessary or 
1 
J improper treatment. I 
I Patient safety. Patient safety is also a concern when prescribing a 
medicine off-label. If the FDA has not approved the medication for the 
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i may experience unknown side effects or the medicine may not work as intended. 
prescribed indication, age, dosage or route of administration, then the patient 
I Often, children, especially infants, may not be able to swallow a medicine via the 
J approved route of administration; for example, a tablet versus a liquid. ) 
Therefore, physicians may prescribe a formulation which is not commercially i 
available and the consequences of the different formulation may not be fully 
known. Also, physiologically, pediatric patients react differently to drugs when 
compared to adults (Cohen, 1997); side effects are of special concern when a 
medicine, approved for adults, is prescribed to children. In these situations, 
physicians must prescribe a medicine off-label to the child and the side effects 
could produce unintended results for the patient. (Conroy, 2002) 
Results of several studies suggest that off-label treatments can lead to a 
higher incidence of side effects. Neubert, et al (2004) found that patients treated 
with off-label medicines had a much higher risk of developing unwanted side 
effects, or adverse drug reactions (ADRs). These researchers prospectively 
evaluated patient charts from a German hospital pediatric ward over an 8-month 
period. Out of a total of 170 patients given 740 prescriptions, 195 medicines were 
prescribed off-label. Of these, 46 ADRs were detected in 31 patients, an overall 
ADR rate of 17.4%. Patients that received at least one medicine off-label 
experienced at least one ADR more frequently than patients who received a 
medicine only in a licensed manner (28.3% vs 7.8%), almost 4 times greater 
chance. 
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Interestingly, these authors also found that when the physician prescribed 
a medicine in an off-label manner, they were more likely to recognize the 
associated ADR than when the ADR was associated with a medicine prescribed 
in an approved manner (43.8% vs 64.3%). This is an important finding because it 
shows that when the physicians prescribed the medicine off-label, they had 
increased their awareness level for ADRs, possibly because they were 
prescribing the medicine off-label. 
A few years earlier, Turner, Nunn, Fielding, and Choonara (1999) had 
similar findings in their 13 week prospective study of prescriptions in children's 
hospital wards in the United Kingdom. Of 4,455 prescriptions given to 936 
patients during the study period, 1,574 (35%) were off-label. ADRs occurred with 
6% of the medicines prescribed off-label but only with 3.9% of the licensed 
medicines, accounting for an increased risk of about 1 .5. 
Horen, Montastruc and Lapeyre-Mestre (2002) reported similar, alth()ugh 
less alarming, results in their prospective study of pediatric drug prescribing 
among 39 office-based physicians in France over a 4 month period. In this 
study, 42% of the 1419 patients received at least one off-label prescription and of 
those prescriptions, 20 ADRs were reported, with the incidence of ADRs for off­
label medicines occurring 2.0% of the time versus 1.4% medicines that were 
prescribed according to their label. Most likely, there were much fewer ADRs 
reported in this study versus the studies done in the hospital because the 
medicines prescribed in the hospital are more powerful as the diseases treated in 
the hospital are much more serious. 
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If an ADR does occur, physicians may be reluctant to report the ADR 
when the medicine was prescribed for an off-label use (Conroy, 2002). Also, 
without knowing the ADRs that occur in patients on a widespread basis, 
physicians may unknowingly subject their patients to ADRs. 
Litigation. Researchers indicate that physicians fear legal complications 
if they prescribe a medicine off-label if their patient has an adverse reaction to 
the medicine or if the medicine is ineffective for the indication prescribed. Blum 
(2002) explains that physicians must be very careful to ensure that the 
information they use to prescribe a medicine to their patients is up to date and 
scientifically valid. As explained previously, the PDR, while a common reference, 
becomes quickly out-of-date and does not include any information about off-label 
prescribing. If a physician is unsure about the safety or efficacy of a medicine 
when prescribed off-label, they may hold back valuable treatments for the patient 
just because the medicine is not approved in the manner it was prescribed 
(O'Reilly & Dalal, 2003). 
Hill (2005) explains that if a physician did not prescribe the best medicine 
for their patient, whether the medicine is prescribed off-label or not, the physician 
could be held liable for any side effects that occur. Several legal cases have 
sided with patients claiming that physicians have not used good judgment when 
prescribing medicines off-label. If a physician is unsure about the latest off-label 
research, they may choose to not prescribe medicines off-label, which could 
mean that a highly effective treatment is withheld from the patient. In order to be 
protected from legal liabilities, physicians must rely on information and guidance 
36 
I 

1 
 from "a respected body of medical knowledge." However, as indicated above, 
finding a reference that is appropriate is not always easy or feasible for the 
physician (Hill, 2005). 
Insurance reimbursement. When a physician prescribes a medicine off-
label, the patient may have difficultly getting reimbursement for the medicine. 
Many prescription benefit companies will reimburse patients only for medicines 
that have been approved by the FDA for the use in which they were prescribed 
(O'Reilly & Dalal, 2003). In situations where off-label treatments may be more 
effective than approved medicines, insurance reimbursement issues can hinder a 
physician's ability to effectively treat a patient. Patients in these situations may 
be forced to pay out-of-pocket for their medicines or be treated with medicines 
that may be less effective for their needs. 
Patient complaints. Lastly, as patients become more educated about 
healthcare, they may be more likely to complain to their physician about the use 
of a medicine in a manner that is not indicated on the medicine's label. 
Physicians, however, want to please their patients. Lowe-Ponsford & Baldwin 
(2000) surveyed 200 psychiatrists to determine how common off-label 
prescribing was in their specialty and to ascertain whether or not they felt 
sufficient prescribing guidelines were available. Although 65% of respondents 
indicated that they prescribed medicines off-label in the last month, only four 
percent had received complaints from their patients regarding the off-label 
prescribing. Although the result is not very significant and the respondents did 
not indicate what the exact complaint was, based on respondent comments, the 
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authors believe that patient complaints are another concern that may influence 
physicians to prescribe a medicine off-label. If patients complain, a physician 
may be less likely to prescribe a certain medicine to their patients, even if the 
medicines prescribed off-label can benefit the patients more than those 
prescribed in a manner indicated on the label. 
New Regulations 
To encourage manufacturers to perform more clinical trials in the pediatric 
population, which would lead to more data about the risks and benefits of the use 
of a specific medicine in this population, in 1997, the FDA enacted the pediatric 
exclusivity program. This program allows the FDA to grant a patent extension to 
a manufacturer if they conduct pediatric clinical trials with their medicines. 
Fortunately, there have been over 100 changes made to product labels due to 
the new data available on the use of the medicine in the pediatric population. 
According to Benjamin, et al. (2006) dissemination of all clinical trial 
results has been limited. Their study suggests that the results of clinical trials 
with positive results are much more likely to be reviewed by the FDA and 
published. These researchers found that positive labeling changes were made 
for only 50% of the studies submitted to the FDA and that results from only 45% 
of studies performed were published in peer reviewed journals. These results 
indicate that although the new regulation has been successful in encouraging 
manufactures to perform pediatric clinical trials, the results from the studies are 
not being published in a manner to ensure physicians understand all the risks 
and benefits of a particular medicine before prescribing it to their patients. 
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Pediatrician Opinion 
While off-label prescribing is prevalent in many patient populations and 
there are many factors associated with the practice, few researchers studied 
physician knowledge and attitudes regarding the practice. Moreover, no 
research is available which explains whether physicians treating children have 
the same factors, knowledge and beliefs regarding the practice as physicians 
that treat adults. This study will add to the body of knowledge regarding off-label 
prescribing in the pediatric population. 
Summary 
The practice of prescribing medicines to children in a manner that has not 
been approved by a regulatory agency (off-label prescribing) can have significant 
effects on the patient, their family and the healthcare community. This literature 
review described the process a manufacturer must follow to receive marketing 
approval for a medicine, reviewed the prevalence of off-label prescribing in both 
the general and pediatric populations and evaluated several concerns of off-label 
prescribing. 
Physicians, who are ultimately responsible for providing medicines to 
patients, must be able to provide patients and their families with adequate, 
balanced information on the benefits and risks of all treatment options, whether 
the options are approved for the prescribed use or not. In order for this to occur, 
physicians must be aware of the risks and benefits of off-label prescribing. In 
addition, they must be able to adequately describe it to their patients. Only when 
both the physician and the patient are properly informed can they both decide on 
1 
1 
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I the best treatment method. Therefore, it is important to understand the reasons 
1 why physicians choose to prescribe medicines off-label to children. The results 
I of this study will provide the background knowledge needed to develop strategies 
to ensure that the medication decisions being made for pediatric patients are the 
most effective and evidence-based. 
1 
i 
t 
1 
J 
i 
I, 
1 
I• 
I 
1 
I 
I 
t 
I 
I 
} 

I 
40 
Chapter III 
Methods 
Subjects 
All members of the New Jersey chapter of the American Academy of 
Pediatricians (AAP/NJ) and the Tennessee chapter of the American Academy of 
Pediatricians (TNAAP) with an email address registered with their respective 
organization were asked to participate in the study. The American Academy of 
Pediatrics (AAP) is a national organization that is "committed to the attainment of 
optimal physical, mental, and social health and well-being for all infants, children, 
adolescents and young adults" (http://www.aap.org/about.html. Accessed April 
30,2008). They provide membership opportunities to pediatricians, pediatric 
medical subspecialists and pediatric surgical specialists. 
TNAAP and AAP/NJ offer benefits and have membership similar to AAP, 
but at the state level. The members of these organizations were chosen as 
subjects for this study because TNAAP and AAP/NJ are the largest groups that 
represent the pediatric profession in their respective states. Surveying two states 
allowed for a greater number of respondents and enabled the researcher to 
determine if pediatrician understanding of off-label prescribing differs based on 
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geographic practice location. These particular two states were chosen due to 
geographic convenience for the researcher while also representing different 
regions of the United States. 
The AAP/NJ has 2,184 members and 1,806 of the members have an 
email address registered with the organization. TNAAP has 1,100 members and 
864 of the members have a working email address registered with the 
organization. Not having a working email address registered with either TNAAP 
or AAP/NJ when the survey was distributed was the only exclusion criterion for 
this study. In order to achieve a medium effect size of .3, a power of .8 and an 
alpha of .05, a minimum of 143 respondents were required (Erdfelder, Faul & 
Buchner, 1996; Portney & Watkins (2000». 
Design and Variables 
This study was a between respondents, descriptive survey design. 
Independent variables. The eight independent variables were the 
answers to the demographic questions. The answers to these questions 
collected general information about the respondents in order to help gain 
information which could account for the answers given for the dependent 
variables. 
The independent variables are the following: (1) name of state in which 
the respondent practices medicine [New Jersey, Tennessee or other], (2) name 
of country in which the respondent attended medical school, (3) name of country 
in which the respondent completed first residency, (4) name of country in which 
the respondent completed fellowship, (5) name of country in which the 
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respondent obtained board certification, (6) whether the respondent was a 
pediatric generalist, surgical specialist or medical specialist, (7) number of years 
the respondent has been a practicing physician and (8) the type of environment 
the respondent works in [solo practice, group practice, teaching or non-teaching 
hospital]. 
Dependent variables. The thirty-two dependent variables were the 
answers to the five research questions. The frequency of use of the 12 
references, 11 therapeutic categories and 5 age ranges identified in the first 
three research questions each had five levels of responses on a Likert scale: (1) 
regularly, (2) often, (3) sometimes, (4) rarely and (5) never. The percent of 
medicines prescribed in the last year had 5 possible responses (none, 1-25%, 
26-50%,51-75%, and 76-100%). The last three dependent variables, the legal 
concerns, patient complaints and personal opinion about off-label prescribing, 
had 6 levels of responses on a Likert scale: (1) strongly agree, (2) agree, (3) 
neutral, (4) disagree, (5) strongly disagree and (6) I do not prescribe medicines 
off-label. 
I 
j 
Instrumentation 
There are currently no available surveys published to determine 
I pediatrician attitudes and beliefs towards off-label prescribing. Therefore, the 
researcher developed an eleven item survey based on the literature that J 
I " 
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describes factors that may influence physicians to prescribe medicine off-label 
(Conroy, 2002). Prior to use, in the current study, the survey was distributed to 
I ten experts in healthcare and research associated with Seton Hall University for 
I 
1 
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face validation. Expertise was defined as possessing a terminal doctoral degree 
in healthcare or a related field, twenty or more years of experience in research 
and the title of Associate Professor or greater. The process utilized for validation 
and the changes made to the survey due to the validation process are described 
in Appendix A and was based on the Delphi method as described by Hyrkas, 
Appelqvist-Schmidlechner, & Oksa (2003), Powell (2003) and Rubio, Berg-
Weger, Tebb, Lee, & Rauch (2003). 
Structure of the survey. The final version of the survey is contained in 
Appendix B. The survey contained four sections: (1) instructions, (2) research 
questions, (3) demographic questions and (4) an open-ended question. 
I The instructions contained a brief consent statement and definitions of 
I terms used in the survey. The terms defined were off-label, regularly, often, 
I 
J 
sometimes, rarely, never, strongly agree, agree, neutral, disagree, and strongly 
disagree. The consent statement indicated that by submitting a completed 
survey, the participant allowed the researcher to use the answers for research 
purposes. 
The second section of the survey contained 5 questions about the 
knowledge, practice and concerns of pediatricians regarding off-label prescribing. 
The first question in this section asked participants to report on the frequency of 
use of 12 different medical references when choosing to prescribe a medicine to 
their patients. The second question asked participants to indicate their use of 
medicines off-label over the last month for 11 different therapeutic categories. 
The third question asked participants to indicate their use of medicines off-label 
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for 5 different patient age ranges. For each of these first three questions, the 
participants were instructed to choose one of the following previously-defined 
choices on a Likert scale: (1) regularly, (2) often, (3) sometimes, (4) rarely and 
(5) never. 
The fourth question asked respondents to report on the percentage of 
medicines they prescribed off-label in the last year, ranging from 0 to 100% in 
five categories (Le. none, 0-25%, 26-50%, 51-75%, and 76-100%). The final 
question in this section contained three individual statements for which 
1 
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participants were asked to report their beliefs about off-label prescribing with 
regard to legal liabilities, patient complaints, and whether off-label prescribing 
should be allowed. The possible responses for these questions were: (1) strongly 
agree, (2) agree, (3) neutral, (4) disagree, (5) strongly disagree and (6) I do not 
prescribe medicines off-label. 
The third section consisted of 5 demographic questions. The following 
information was collected about the respondents via multiple choice answers: 
state in which they practiced medicine, whether specialist or generalist, years 
working as a pediatrician, and working environment. In addition, the 
pediatricians were asked to provide the name of the country where they attended 
medical school, completed residency, completed fellowship and obtained board 
certification. 
The final section of the survey consisted of one open-ended question 
which gave the partiCipants an opportunity to share any additional information 
about off-label prescribing. 
I 
I 
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Data Collection 
The survey was hosted on SurveyMonkey (www.surveymonkey.com). a 
secure website for creating and hosting web surveys. The participants were 
required to log on to the website via a unique Universal Resource Locator (URL) 
to access the survey. SurveyMonkey.com ensured that there were no duplicate 
responses from the same IP address which prevented participants from 
completing the form multiple times. 
Confidentiality and anonymity were maintained as no personal, identifiable 
information about the participants was collected. Participants were unable to 
view the responses of other participants or any summary of responses which 
could cause bias or pose as a potential influence. 
Prior to obtaining approval of the research protocol by the Institutional 
Review Board (lRB) for Human Subjects Research at Seton Hall University, the 
researcher contacted the Executive Director of the TNAAP and the President of 
the AAP/NJ to determine their interest in participating in the study. Both 
organizations agreed to participate and provided the researcher with written 
approval for their participation. The written approval indicated that the TNAAP 
and AAP/NJ staff agreed to be the conduit between the researcher and the 
subjects by distributing the survey to all members of their associations that have 
an email address registered with their association. They also agreed to send two 
reminders, one at two weeks and one at four weeks after the initial invitation, to 
all individuals who received the initial invitation (Appendices C and D). 
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Following approval by the IRB (Appendix E), the researcher developed 
and sent emails (Appendices F, G and H) to the Executive Directors of the 
TNAAP and AAP/NJ asking them to forward the email to all members of their 
association with email addresses registered with their respective associations. 
The emails brielly explained the purpose of the study and invited the recipients to 
complete the survey. The emails included a link for the subjects to click on which 
brought them to a website, which included the survey instructions, applicable 
definitions and the survey. If the email recipient chose to participate, they 
completed the survey on-line and submitted their responses to the Survey 
Monkey host location. 
The first email was sent to both individuals by the researcher on May 14, 
2009, the second email was sent May 31,2009 and the final email was sent on 
June 15, 2009. While data collection was ongoing, all information collected was 
stored on SurveyMonkey.com and only the researcher had access to this 
information. The survey was available for access from May 14,2009 to July 6, 
2009. After July 6,2009, the researcher downloaded the survey answers 
directly from the survey website and saved it to two USB drives, one which 
remained in a locked, secure cabinet in the researcher's home office and one 
which remained in a locked, secure cabinet in the researcher's professional 
office. After analyzing the data using SPSS, the researcher saved all information 
related to the study on a CD, in a locked cabinet, in the researcher's home office. 
No other people had access to the data. 
Data Analysis 
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Data obtained from each of the submitted surveys were coded and 
downloaded to the Statistical Package for Social Sciences (SPSS) Version 17.0 
for data analysis. Prior to analyzing the data, the questions utilizing a Likert 
scale were coded. Questions 1-3 were coded as follows: 1= regularly, 2=often, 
3=sometimes, 4=rarely and 5=never. Question 5 was coded as follows: 
1 =strongly agree, 2=agree, 3=neutral, 4=disagree, 5=strongly disagree and 6=1 
do not prescribe medicines off-label. 
Statistical analysis. The researcher analyzed the data using both 
descriptive and non-parametric statistics. With descriptive statistics, the 
researcher was able to describe the central tendency and variability of the data to 
describe the population (Portney & Watkins, 2000), in this case, the factors that 
may affect off-label prescribing. Specifically, frequencies and lor percentages 
were reported to examine trends in the following independent variables: years of 
practice, specialty, practice type, country educated and practice location. The 
results of these tests enabled the researcher to describe the demographics of the 
population surveyed. Means and frequencies were calculated to examine trends 
in the following dependent variables: off-label prescribing concerns, percentage 
of drugs prescribed off-label in the last year, therapeutic categories of off-label 
prescriptions, references used, and age range(s) of patients. 
Two non-parametric statistics, the chi-square test of association and 
Spearman's rho, were used to analyze the relationships of the variables in this 
study. The chi-square test examines the association between the variables and 
cross tabulations were used to describe the association of many variables at one 
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time. Spearman's rho, used to determine relationships among ordinal data, was 
used to analyze the relationships between the dependent variables in this study 
(Portney & Watkins, 2000). 
The Chi Square tests analyzed relationships between the independent 
and dependent variables {e.g. whether or not pediatricians educated outside of 
the United States prescribe more medicines off-label than those educated in the 
United States}. The Spearman's rho tests analyzed the relationships between 
the dependent variables (e.g. whether or not pediatricians with more concerns 
about off-label prescribing prescribe medicines off-label less often than 
pediatricians that have less concerns about off-label prescribing). 
An alpha level of pS.05 was considered significant for all statistical tests 
(Portney & Watkins, 2000). 
Analysis of responses to open ended question. The qualitative data 
received from the last question of the survey were analyzed for emergent 
themes, which were then compared with the quantitative data received from the 
other survey questions. In addition, keyword analysis and topic grouping was 
used to analyze the response to the open ended question in order to develop 
future research questions and enable the researcher to interpret the qualitative 
data with respect to the quantitative data. 
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Results 
Study Sample 
Of the 2670 email requests to participate in the survey, a total of 167 
individuals accessed the survey and responded to at least one survey question 
(response rate = 6.25%). As indicated earlier, 143 responses were required 
based on the power analysis. Because respondents were not required to provide 
I answers to all survey questions, all surveys submitted, regardless of whether all 
questions were answered, were included for analysis. 
Demographic characteristics of the study sample. The demographic 
characteristics of the study sample (years in practice, specialty, practice type, 
country educated and location of practice) were analyzed using means, standard 
deviations and frequencies. The demographics of the study sample were then 
compared to the questions regarding off-label use to determine if there are any 
relationships between the demographics and beliefs and practices regarding off-
label prescribing. 
Almost two-thirds of the respondents indicated that they practice medicine 
in Tennessee (n=104, 62.3%), 58 (34.7%) indicated that they practice in New 
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Jersey, 3 respondents (1.8%) indicated another state and 2 respondents (1.2%) 
did not respond to the question (Figure 2). 
Figure 2. State in which respondents practice medicine 
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The number of years, post residency, that the respondent has been a 
practicing physician is shown in Figure 3. Twenty-five (15%) respondents had 
less than 5 years of experience, forty-six (27.5%) had 5-15 years of experience, 
fifty-two (31.1 %) had 15-25 years of experience and thirty-six (21.6%) had over 
twenty-five years of experience. Seven respondents (4.2%) indicated they were 
residents and one respondent (0.6%) did not answer the question. 
Figure 3. Number of years respondent has been a practicing physician 
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Regarding pediatric specialty, the majority (n=119, 71.3%) of respondents 
reported that they were pediatricians, with no specialty. Forty respondents (24%) 
indicated that they were pediatric medical subspecialists, and 3 respondents 
(1.8%) indicated that they were pediatric surgical specialists. One respondent 
(0.6%) indicated that they were an administrator in a pediatric hospital and one 
respondent indicated that they were a pediatric resident. Three respondents did 
not answer this question. 
Regarding their working environment, six percent of respondents (n=10) 
indicated they worked in a solo practice, 51.5% (n=86) in a group non-hospital 
based practice, 7.8% (n=13) in a non-teaching hospital based practice and 
33.5% (n=56) in a teaching-hospital based practice. Because respondents were 
allowed to select more than one answer, the total number of responses for this 
question exceeds the total number of respondents. 
The majority of the respondents reported that they attended medical 
school in the USA (n=145, 86.8%). The remainder of the respondents attended 
medical school in 14 other countries which are listed in Table 1. 
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Table 1. Country in which respondents attended medical school 
Country Freguenc~ Percent 
No answer 1 0.6 
Brazil 2 1.2 
Colombia 2 1.2 
Czech Republic 1 0.6 
Germany 1 0.6 
Grenada 2 1.2 
India 3 1.8 
Jordan 1 0.6 
Lebanon 1 0.6 
Mexico 1 0.6 
Nigeria 2 1.2 
Pakistan 1 0.6 
Philippines 2 1.2 
Saint Kitts 1 0.6 
USA 145 86.8 
West Indies 1 0.6 
Total 167 100 
One hundred sixty three (97.6%) respondents indicated that they 
completed their first residency in the USA. One respondent did not answer the 
question and three other respondents indicated that they completed their first 
residency in other countries, namely Brazil, India and Lebanon. 
About half of respondents (n=76, 45.5%) indicated not applicable to the 
question regarding where they completed their fellowship. Twenty-one 
respondents (12.6%) did not provide an answer to this question and 70 
respondents indicated that they completed their fellowship in the USA. As 
fellowships are not required in all medical specialties, the response to this 
question was not surprising. 
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The majority of respondents also indicated that they obtained board 
certification in the USA (n=155, 92.8%). The remainder of the respondents either 
indicated not applicable (n=9, 5.4%) or did not provide a response to this 
question (n=3, 1.8%). 
Overall, therefore, the study population reflects general pediatrician 
population in the United States in terms of specialty, practice type, number of 
years respondents practiced medicine, and the country in which the respondents 
attended medical school, completed first residency and completed their first 
fellowship and was Board Certified (Smart, 2009). 
Frequency of Off-label Prescribing 
Figure 4 indicates that almost three quarters of the respondents (73.1 %) 
prescribed medicines off-label 1-25% of the time in the last year. 
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Figure 4. Frequency of percent of off-label prescriptions in the last year 
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Use of References for Medication Prescribing 
Respondents reported that, most often (43% indicated regularly used), 
they use reference manuals to determine which medicines to prescribe to their 
patients (mean 1.92, indicating an average ranking of often) and that they use 
unpublished research least often (49% indicated never used) for determining 
whether to prescribe a medicine to their patients (mean 4.41, indicating an 
average ranking between rarely and never). 
The other references, ranked from greatest to least used, are as follows: 
published, peer-reviewed research (mean 1.96), medicine's label (mean 2.01), 
previous experience (mean 2.01), group! hospital! facility! office's experience 
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(mean 2.20), peer recommendations (mean 2.46), pharmaceutical representative 
(3.54), patient's insurance company (mean 3.59), patient! guardian's request 
(mean 3.61), published, not-peer reviewed research (mean 3.68), and patient I 
guardian's suggestion (mean 3.74). 
Interestingly, the references with the least consistency in use (highest 
standard deviation) were the medicine's label and the patient's insurance 
company, with standard deviations of 1.078 and 1.191, respectively. Table 2 
provides detailed information on the number of respondents who used each 
referenced resource to determine whether to prescribe a medicine to their 
patients and their individual means and standard deviations. 
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Table 2. Materials respondents use to determine whether or not to 
prescribe medicine to their patients 
I use the following to determine whether or not to Standard 
prescribe medicine to my patients: N Mean deviation 
The medicine's label 162 2.01 1.078 
Published, peer-reviewed research 164 1.96 0.929 
Reference manuals 166 1.92 0.956 
Published, not peer-reviewed research 161 3.68 0.885 
Unpublished research 162 4.41 0.665 
My previous experience with the medicine 164 2.01 0.95 
My group/ hospital! facility / office's experience 163 2.2 0.995 
with the medicine 
Peer recommendations 163 2.46 0.884 
Information from a pharmaceutical representative 162 3.54 0.985 
The patient's insurance company 161 3.59 1.191 
The patient / guardian's suggestion 163 3.74 0.736 
The patient / guardian's request 162 3.61 0.798 
Off-label Prescribing by Therapeutic Area 
Of all the therapeutic areas included in the survey, respondents reported 
that they prescribe antibiotic medicines in an off-label manner, most often (mean 
3.63, indicating an average ranking between sometimes and rarely) and insulin, 
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least often (mean 4.90, indicating an average between rarely and never but very 
close to never). 
The other therapeutic areas, which were ranked from greatest to least 
prescribed off-label, are as follows: anti-asthmatic (mean 3.75), anti-histimifle 
(mean 3.80), dermatologic (mean 3.90), analgesic (mean 3.96), rhinological 
(mean 4.23), expectorant and anti-tussive agents (mean 4.27), otologic (mean 
4.44), psycholeptic and psychoanaleptic (mean 4.48), and anti-epileptic (mean 
4.51 ). 
The therapeutic area with the highest noted standard deviation was anti­
asthmatic, at 1.294. This indicates that this therapeutic area had the most 
variability in response around the mean. The therapeutic area with the least 
variability was insulin, .361, indicating little variability in responses around the 
mean. Table 3 indicates the frequency that the respondents prescribe medicines 
off-label for each therapeutic area and their individual means and standard 
deviations. 
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.~ Table 3. Medicines prescribed off-label in various therapeutic areas once 
1l per month, at minimum (total n= 164) 
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3.96 
3.75 
4.51 
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3.8 
3.9 
4.27 
4.9 
1.164 
1.294 
0.825 
1.176 
1.098 
1.061 
0.889 
0.361 
otologic 164 4.44 0.736 
psycholeptic and psychoanaleptic 163 4.48 0.958 
rhinological 163 4.23 0.938 
Off-label Prescribing by Age 
When asked what age ranges respondents prescribed medicines off-label 
to in the last month, there was no significant difference in the means and 
standard deviations for the different age ranges provided less than 18 years of 
age. The mean for less than one year old was 3.52, for 1-5 years old was 3.43, 
for 6-12 years old was 3.50, and for 13-17 years old was 3.55, which all indicate 
an average ranking between sometimes and rarely. The standard deviations 
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were 1.320, 1.136, 1.116 and 1.093, respectively, which indicates that there was 
some variability around the mean for these age ranges. 
For patients 18 years and older, the mean was 4.07, indicating an average 
ranking of 4.07, between rarely and never, and the standard deviation was .944, 
indicating less variance around the mean than for all other age ranges. 
Off-label Prescribing Beliefs 
Regarding their beliefs about off-label prescribing, with a mean of 2.90, 
respondents reported that they felt slightly concerned about legal liabilities or 
were neutral in their response. The standard deviation, however, was 1.288, 
indicating some variance around the mean. 
Respondents indicated that they disagree that they are concerned about 
patient or guardian complaints when they prescribe a medicine off-label or were 
neutral in their response (mean 3.59). The standard deviation for this question 
was 1.110, indicating some variability around the mean. 
Respondents indicated that they believe that physicians should be allowed 
to legally prescribe medicines off-label, as the mean for the question "I believe 
that physicians should not be legally allowed to prescribe medicines off-label" 
was 4.23, with the average ranking between disagree and strongly disagree. The 
standard deviation was 1.118, indicating some variability around the mean. 
Nonparametric Statistical Analysis 
The Chi-square test of association was used to analyze relationships 
between the dependent and independent variables using cross tabulations. 
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Spearman's Rho was used to analyze the relationships between the dependent 
variables. Only the analyses that met the criteria for statistical significance of 
p~.05 are described in this section. 
The first set of analyses conducted were to determine if there was a 
relationship between the state in which the respondent practiced medicine and 
the following dependent variables: materials respondents use to determine 
whether to prescribe a medicine to their patient, medicines in various therapeutic 
areas respondents prescribed off-label in the last month, respondents beliefs 
regarding off-label prescribing and the percent of medicines the respondents 
prescribed off-label in the last month. 
Regarding materials used to determine whether to prescribe a medicine 
to their patients, there was a significant relationship between state in which the 
respondents practiced medicine and the medicine's label (p=.021), the 
respondent's group/ hospital! facility / office's experience with the medicine 
(p=.021) and peer recommendations (p=.OOO). 
The only therapeutic area in which the respondent's state and whether the 
respondent prescribed medicines off-label in that therapeutic area in the last 
month had a statistically significant relationship was for analgesic medicines 
(p=.006). The only belief that had a statistically significant relationship with the 
respondent's state was legal liabilities (p=.011). 
The second set of analyses conducted were to determine if there was a 
relationship between the therapeutic area of medicines prescribed off-label and 
the pediatric specialty (pediatrician, medical subspecialist or surgical 
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subspecialist) of the respondent. For this analysis, two therapeutic areas met the 
criteria for statistical significance of p:5.05: whether the respondent prescribed 
expectorant and anti-tussive agents off-label in the last month (p=.011) and anti­
histirnine medicines (p=.01 0). 
For all these associations, the results must be interpreted with caution, as 
there were numerous cells that had a count of less than 5 responses per cell J3nd 
with such a small number of responses, the results may not be indicative of the 
beliefs of the general population. 
Qualitative Analysis 
Since there is little research available which looks at off-label prescribing 
from the prescriber's point of view, the last question of the survey asked 
respondents to include any additional information they would like the researcher 
to consider about off-label prescribing. The themes that emerged from the 
responses allowed the researcher to put the quantitative responses into context 
as well as develop further avenues to pursue when studying off-label prescribing 
(Graneheim & Lundman, 2004). 
A total of 40 respondents provided comments to the last question of the 
survey. The responses were grouped into seven categories based on keywords 
within the responses. 
The first category contained a total of 13 responses that indicated that 
either the respondent was a specialist and the majority of the medicines they 
prescribe are off-label or that the respondent was a general pediatrician that 
relied heavily on specialists for prescribing medicines off-label to their patients. 
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An example of a response in this category was '" do weight heavily the off-label 
use of medications by pediatric subspecialists in deciding whether it is either safe 
or efficacious to use a particular medication. It would seem that the 
subspecialists are the "first to choose a drug for off-label use. If it is successful in 
the patients I have referred to them, and if I see increasing numbers of patients 
being treated that way, I am more likely to try it off-label myself." 
The second category contained 11 responses in which respondents 
indicated that they believe that the majority of the off-label prescribing that they 
engage in is related to the age of their patient. They further indicated that they 
rely on evidence-based data on adults to assist them in determining whether they 
should prescribe a medicine to their child, indicating that they attempt to use an 
evidence-based approach to making their prescribing decisions. 
The third category that emerged from respondents' comments supported a 
disappointment with the lack of evidence-based data regarding the use of many 
medications in the pediatric population. Specifically, five respondents indicated 
that while they do not like prescribing off-label to their patients, they feel forced to 
because of the lack of approved medications in this population. An example of a 
response in this category was "it is difficult to find enough drugs approved for the 
less than 12 month old." 
I 
The fourth category contained responses from 4 respondents. These l 
respondents indicated that they prescribe only certain medicines off-label to their 
patients given they can based their prescribing decision on their previous I 

experience with the medication thus supporting that prior knowledge does playa 
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key factor in prescribing practices. An example of a response in this category 
was "I prescribe hydroxyurea to children with sickle-cell disease on a regular 
basis because, based on my experience, it is effective for these patients." 
Interestingly, only two respondents indicated that they do not inform the 
patient or their guardian when they prescribe medicines off-label to them and 
also do not discuss the medication risks and potential other options of care. This 
suggests that communication may be factor in decision making for some 
physicians. 
Only, one respondent indicated that they were not aware what medicines 
were off-label anymore. Two respondents provided non-content specific 
responses to this question: one further clarified their use of the word rarely for 
responding to the survey questions and one respondent indicated that their 
answers to the survey may have been different if they were still practicing 
medicine. 
Summary 
A total of 167 individuals provided answers to an on-line survey regarding 
their beliefs and practices toward off-label prescribing. 
The hypotheses that pediatricians would report that the primary factors 
that influence their decision whether or not to prescribe a medicine off-label are a 
lack of appropriate references and concerns about patient safety and the 
secondary factors that influence their decision whether or not to prescribe a 
medicine off-label are legal concerns, insurance coverage and patient complaints 
were not fully supported by the results of this study. 
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Interestingly, respondents indicated that they use reference manuals most 
often, with published, peer-reviewed research a close second. These results are 
promising because, as indicated in chapter 2, the problem with reference 
manuals is that they may not contain the most up-to-date research regarding a 
medicine and published, peer-reviewed research is the best way to supplement. 
Additionally, this may offer support that physicians are aware of the need to 
practice in an evidenced based manner using the currently available evidence to 
support and direct their clinical decision making. 
However, given the significant variance (1.078) in the use of the 
medicine's label for prescribing information, one must question their practices as 
the drug's label contains the most up-to-date information about the health 
authority-approved uses for the medicine. Thus, this finding may suggest that 
some respondents may not be prescribing a medicine in a manner not approved 
by a health authority. 
Regarding their beliefs about off-label prescribing, respondents did not 
feel strongly about the legal liabilities or patient complaints related to off-label 
prescribing but did believe that physicians should legally be allowed to prescribe 
a medicine off-label. 
Yet, given that almost two-thirds (73%) of respondents indicated that, in 
the last year, they prescribed medicines off-label less than 25% of the time and 
none of the therapeutic areas listed in the survey supported that they prescribed 
off-label medications regularly or often, off-label prescribing does not seem to be 
prevalent in this physician population. Taken together, this data suggests that 
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pediatricians prefer to practice autonomously using and evidence-based 
approach which may explain why they do not prescribe medicines off-label a 
significant portion of the time regardless of practice setting. 
Considering that most of the respondents were not medical or surgical 
specialists and many worked in an outpatient facility, the overall results of the 
study are not surprising. As indicated in chapter 2, medicines are prescribed off­
label more often for the more serious, specialized diseases where the patient is 
typically seen in the hospital or by a specialist (O'Reilly and Dalal, 2003) and, 
therefore, the pediatricians working in these areas are more likely to prescribe 
medicines off-label and have concerns about the practice. 
While the results of the quantitative questions within the survey provided 
valuable insight into the beliefs and practices of pediatricians toward off-label 
prescribing, the answers to the qualitative question were similarly revealing. 
Many respondents indicated that they believed that the references currently 
available were inadequate and that, often, pediatricians rely on specialists to 
prescribe medicines off-label. This finding is also in line with previous research 
that indicates that generalists often do not prescribe medicines off-label (O'Reilly 
and Dalal, 2003). 
The qualitative findings of this study support previous literature that 
indicates that there is a need for more research in the pediatric population. In 
addition, the results indicate that pediatricians are concerned about the safety 
and efficacy of the medicines they prescribe to their patients and would like to 
have evidence-based results prior to prescribing a medicine to their patient. 
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Certainly if a medicine is prescribe in the manner indicated on its label, then that 
means that it has been tested and found to be safe and effective. 
As the results of this study indicate, pediatricians have concerns about 
prescribing a medicine off-label because information about the proper use of the 
medicine may not be available. With the absence of evidence-based research, 
pediatricians must utilize their critical thinking skills and develop practice based­
evidence to determine the best medicine to treat their patient (Horn & Gassaway, 
2007). 
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Chapter V 
Discussion and Conclusions 
The purpose of this study was to determine pediatrician beliefs toward off­
label prescribing and the factors that may influence their decision to prescribe a 
medicine off-label. The results of this study indicate that pediatricians prescribe 
medicines off-label and most reported that they do so no more than 25% of the 
time. Respondents also indicated that some pediatricians have little experience 
with off-label prescribing and, often, there are no references, based on evidence 
-based practice, that clearly define how medicines should be prescribed off­
label. 
The results of this exploratory study set the stage for the initial dialogue 
regarding off- label prescribing practices in the pediatric population in a scholarly 
venue. While this contribution, in of itself. is important to the practice of health 
care in the United States, this work sheds light on the importance of the health 
care community specifically physicians, who as autonomous practitioners have 
the right and privilege to prescribe medications off-label, to practice their craft 
using the best available evidence. 
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Two key factors that can be used to support evidenced based practice 
which resonate from the findings of this study are the importance of practice 
based evidence and ongoing training for health care professionals. 
Practice-based Evidence 
One way to address the lack of evidence-based practice is to develop 
guidelines based on observed current practices. Horn and Gassaway (2007) 
describe this method as practice-based evidence (PBE). PBE is developed by a 
multisite, trans-disciplinary Clinical Practice Team whose responsibility is to 
analyze patient data within their practice to develop guidelines for members of 
their clinical team. The team does not need to publish the data or rely on others 
to approve their guidelines; they just need to ensure there is observable evidence 
to justify the processes suggested. 
Other benefits of PBE are that the data that is analyzed is based upon 
patient treatments and therapeutic outcome data that is normally collected in 
medical practice and therefore, does not require patient consent. Also, the 
guidelines developed can be modified quickly based on new information, 
evidenced based observations or treatment outcome data. Thus, health care 
team does not need to wait for regulatory approval or the publication of evidence­
based practices; the team can re-train and improve their practices as necessary 
based upon PBE. 
Training 
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Training is another issue that was highlighted in the results of this study. 
Many physicians felt that additional training is needed to determine the risks and 
benefits related to off-label prescribing as well as when the practice is 
appropriate or not. The issue is how to develop training that will be effective., 
Generally, after the completion of their internship, any and all training that a 
physician receives is through continuing medical education (CME) (Davis, 1998). 
Several studies (Holm, 1998; Fox & Bennett, 1998; Mathers, Challis, Howe & 
Field, 1999; Grol, 1992; Bashook & Parboosingh, 1998) present theories for how 
to effectively and efficiently provide CME to physicians as well as how to change 
a physician's prescribing behavior through CME (Denig, Wahlstrom, Chaput de 
Saintonge, Haaijer-Ruskarnp, 2002; Gill, Makela, Verneulen, Freemantle, Ryan, 
Bond, et ai, 1999). 
Interestingly, Verniga, Denig, Zwaagstra, and Haaijer-Ruskamp (2000) 
studied the effects of cognitive feedback on a physician's choice of treatment for 
patients with asthma and urinary tract infections. Their parallel, randomized 
controlled study included 24 already existing pharmacotherapy counseling 
groups in the Netherlands, each with about 7 physicians per group. The 
researchers provided half of the groups with national guidelines, case studies 
and individual and group feedback on the prescribing choices made for the 
treatment of asthma and half of the groups received this information of urinary 
tract infections (UTls). Each set of groups acted as a control group for each 
condition. Lastly, the researchers collected the 6 months of prescribing data 
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before the intervention and 6 months of prescribing data after the intervention to 
determine whether there were any changes in prescribing behaviors. 
While the results of this study showed some improvement in prescribing 
behaviors, they showed no significant improvement in participants' knowledge. 
The intervention for the asthma groups did not, on average, improve participants' 
knowledge of the condition, yet there was an 11% to 68% improvement for the 
treatment of different patients with asthma (e.g. treating with inhaled vs. oral 
steroids). For the UTI groups, there was little improvement in knowledge of the 
disease or treatment choices but there was a significant effect on the duration of 
treatment (decreased from an average of 6.07 to 4.29 days on treatment.) This 
suggests that although physicians may have sufficient knowledge about a 
condition, providing them with approved guidelines and feedback on appropriate 
prescribing can improve their prescribing behavior. 
Another way to change pediatrician prescribing behavior is described by 
Fox and Bennett (1998) and is based on adult learning theory. They suggest that 
in order to influence a change in physician behavior, physicians need to first 
identify the deficiencies in their own knowledge and experience and then critically 
evaluate the new information to influence the change. Ultimately, the physicians 
must believe that they need to change their behavior in order to effectively 
practice. They explain that the motivation comes from a physician who estimates 
where they should be in terms of knowledge or skills and then compares it to 
what they actually know or do. Surprisingly, only if the physician discovers a 
discrepancy do they become motivated to learn and address that gap in their 
72 
knowledge. Thus, leaving change in the hands of the physician who may not be 
aware of their limitations, but who has the right and privilege to prescribe off ­
label. Hopefully, if more research is made available that describes the risks and 
benefits of off-label prescribing as well as off-label practicing patterns, physicians 
may self-reflect upon their knowledge of, comfort of and current off-label 
practices and see it as an area to improve their prescribing practices. 
Clinical Judgment Analysis 
Once PBE is established and effective training programs are developed, a 
pediatrician, or any health care professional, ultimately needs to include the new 
practices into their decision making processes for prescribing. The Clinical 
Judgment Analysis model, as described by Denig, Wahlstrom, Chaput & Haaijer 
(2002), indicates one way in which PBE and training would influence prescribing 
decision making practices. The Clinical Judgment Analysis model (Figure 5) 
indicates that there are several informational cues that enable a physician to 
make a decision. These cues can be a patient's signs or symptoms, laboratory 
test results, patient preferences, etc. The model suggests that each individual 
physician weighs the relative importance of each of the information cues 
differently based on their knowledge of what the optimal decision is versus their 
own personal experience or knowledge and then makes the final judgment or 
decision. 
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Figure 5. Clinical Judgment Analysis Model 
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As suggested above and further explained by Denig, et al (2002). the key 
to clinical judgment analysis is the knowledge and expertise of the physician 
regarding the specific decision that needs to be made. The authors believe that 
the Clinical Judgment Analysis Model looks behind the outcome of a decision to 
the underlying decision process and combines ideas from adult learning, 
behavioral change and decision making theory to improve prescribing decisions. 
Both PBE and effective training could lead a physician to support their final 
prescribing decision because they can assist them in reflecting on the influence 
and relevance of the information cues. If off-label prescribing is included as an 
additional informational cue in the clinical judgment model then it can further 
support a physician in making a better prescribing decision for their patient. 
Finally, the authors suggest that educators could develop a set of case 
studies with informational cues for physicians to analyze. Using the case study 
approach further insight on the physicians use of the cues in order to make 
prescribing decisions could be explored and thus further support the adult 
learning process via feedback to the physician. In the literature it has been 
suggested that through this direct feedback that physicians learned and were 
able to make changes to their prescribing behavior. These findings support the 
possibility that case studies can be effectively used in a similar fashion to inform 
and educate the decision making practices of pediatricians with regard to off­
label practices. Specifically, physicians could be provided with a set of case 
studies, based on PBE, which present various situations where off-label 
prescribing may be necessary. Then, through the analysis of the case studies, 
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pediatricians could determine the best options for their patients, thus creating 
PBE and establish effective training on that practice. 
Overall, the results of our study and those in the literature support that 
while no single strategy can change a physician's behavior, the most successful 
strategies are based on the theories of adult learning and behavioral change that 
require physicians to critically think about and analyze their decisions. Clearly, 
these findings further explain our data in a meaningful manner and offer insight 
into future directions for research and education. Given that the respondents of 
this study indicated that they had varying levels of years of experience practicing 
medicine and the absence of significant differences in off-label prescribing 
practices among the different levels of experience one might suggest that aCME 
course that included an element for developing their critical thinking skills, could 
assist pediatricians, at all levels of experience, in critically reviewing and 
assesses all e evidence available to support that use, whether it is EBP or PBE. 
Limitations 
The respondents that completed the survey represented a convenience 
sample of volunteers who learned about the survey through their membership of 
either the AAP/NJ or TNAAP. While about two-thirds of the respondents 
indicated that they practice medicine in TN and about one-third in NJ, the survey 
results may not be representative of the views or practices of other pediatricians 
who are members of these organizations or, furthermore, of those that practice 
medicine in NJ or TN. 
I 
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One of the limitations of this study was the difference in size between the 
number of specialists and general pediatricians. As the qualitative results 
indicated, some generalists rely on the specialists to prescribe medicines off­
label. Since 119 of the respondents were general pediatricians and only about 
45 of the respondents were specialists, it was not ideal to calculate group 
differences since the sizes of the groups were so disparate. 
Another limitation involved the use of an anonymous, on-line survey to 
collect the data. Although Surveymonkey.com prevented the same person from 
answering the survey using the same computer by blocking their IP address after 
they completed the survey, this could have been circumvented by use of an 
alternate computer. The anonymity also prevented the researcher from verifying 
the answers from each of the respondents. Specifically for the questions that 
required respondents to recall their prescribing patterns over the last month or 
the last year, chart verification could have yielded more accurate results. The 
questions which used a Likert scale assumed that the categories had equal 
intervals between them, which is unlikely. Lastly, the use of a survey inherently 
is a limitation because surveys only collect perceptions I opinions and may not 
accurately reflect the behaviors of the respondents. 
Future Research 
The purpose of this research study was to determine the beliefs and 
factors that may influence a pediatrician to prescribe medicines off-label. The 
results of this study should be used to encourage pediatricians to seek more 
guidance and training on the best use of off-label prescribing practices. The 
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results of future research involving a larger population, face to face interviews 
with pediatric specialists or chart reviews could further support the findings of this 
study_ 
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Abstract 
Published literature indicates that the prescribing of off-label 
medicines to children is common. However, few researchers have surveyed 
pediatricians to determine their attitudes and beliefs toward this practice and no 
surveys used in these studies have been validated by research and healthcare 
experts. The purpose of this research project was to develop and validate a 
survey that will be used to determine the attitudes and beliefs of New Jersey 
pediatricians towards off-label prescribing. Ten experts were asked to comment 
on the appropriateness, clarity and sequence of the survey questions. Seven 
experts responded to the request. Overall, only minor changes were 
incorporated into the survey. 
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Introduction 
A medicine that is prescribed off-label is prescribed in a manner that has 
not been approved by a health authority. Although off-label prescribing is legal, 
many researchers have expressed concerns about the use of medicines in this 
manner, indicating that medicines prescribed off-label may not be safe and/or 
effective. These concerns are especially common in the pediatric population 
because of the significant physiological changes occurring in the pediatric 
population (Cohen, 1997). 
Several studies have been performed globally to indicate the prevalence 
of off-label prescribing in the pediatric population. Results of these studies 
indicate that up to 63% of medicines prescribed to children are off-label 
(Pandolfini & Bonati, 2005). Researchers suggest several reasons for the 
widespread use of off-label medicines in this population such as lack of 
resources to perform clinical trials in this population (Conroy, 2002) and lack of 
appropriate references and training on how to properly medicate children 
(Matsui, Jardine, Steer, Cukernik & Rieder, 2003). However, only two studies 
indicate the attitudes and beliefs of physicians towards this practice (Ekins­
Daukes, Helms, Taylor & McLay, 2004 and McLay, Tanaka, Ekins-Daukes & 
Helms, 2006). Because the physician ultimately provides the prescription to the 
patient, it is important that their perspectives of off-label prescribing are properly 
understood by those wanting to make changes to this practice. 
88 
The Elkins-Daukes et al and McLay et al studies include the results of a 
survey given to over 200 general practitioners in Scotland indicating their 
attitudes and beliefs towards off-label prescribing. However, neither study details 
the methods used to develop and validate the survey tool used to collect the 
study data. Therefore, it is important that a survey used to determine the 
attitudes and beliefs of pediatricians towards off-label prescribing is developed 
and properly validated by experts in research and healthcare. 
Methods 
A survey consisting of instructions, 5 research questions, 5 demographic 
questions and 1 open ended question for additional comments was developed 
based on the review of published research in the area of off-label prescribing to 
children (Appendix 1). Each question contains multiple choice, Likert-scale or 
open ended answers. Validation of the sequence, appropriateness, 
completeness and clarity of the survey questions was obtained by mailing printed 
copies of the survey to ten experts in healthcare and research affiliated with 
Seton Hall University. Expertise were defined as possessing a terminal degree 
in healthcare or related field, 20 or more years of experience in research and a 
title of associate professor or greater. 
Along with a copy of the survey, an introduction letter (Appendix 1) was 
provided which included a brief summary of the purpose of the study, definitions 
of terms and references used in the survey, and the researcher's contact 
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information in case the expert had questions about the survey. The experts were 
asked to answer 2-4 questions per survey question, each allowing the expert to 
report whether the sequence, appropriateness, completeness and clarity of the 
questions were suitable for the study. Each question for the experts contained 
two possible answers - yes and no. If the response was no, the experts were 
asked to provide suggestions for improvement. A self-addressed stamped 
envelope was included along with the survey and the experts were asked to 
return completed surveys back within 2 weeks of receipt. Seven responses were 
received within the study timeframe. Overall, only a few questions have been 
changed due to the survey validation results. The final survey can be found in 
Appendix 2. 
Results 
Analysis 
Below are summaries of the responses per question. Only responses 
received by two or more experts (29% or more) were considered for revision. 
Survey Instructions 
Five experts (71 %) believed that the survey instructions were both 
appropriate and clear. Two experts (29%) did not comment on the 
appropriateness or clarity of the survey instructions. No experts believed that the 
instructions should change in any manner; therefore, the instructions remained 
unchanged in the final version of the survey. 
f 
I 
I 
I 
I 
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Question 1. The purpose of question 1 was to determine the reference(s) 
pediatricians use to prescribe medicines to their patients. The experts were 
asked whether the question was appropriate for the study, clear, in the correct 
sequence and complete. All but one expert provided answers for this question. 
Six respondents (86%) believed question 1 was appropriate for this 
survey. Only one respondent believed that question 1 was not clear. Two 
experts (29%) believed that the sequence of the statements in question 1 were 
not suitable. Both experts suggested that the list be presented in order from 
least scientific I evidence-based to most scientific I evidence-based. Because 
two experts reported this opinion, meeting the previously set criteria for making 
changes to the survey, the sequence of the answers for this question has been 
changed in the final version of the survey. 
Two experts believed that additional references should be added to 
question 1. One expert suggested that the Merck Manual be added to the list 
and the other believed that Personal Digital Assistants (PDAs) should be added. 
Because these suggestions do not meet the previously set criteria of two experts 
providing the same suggestion, the reference list will remain unchanged in the 
final version of the survey. 
Question 2. The purpose of question 2 was to determine the therapeutic 
categories pediatricians most often prescribe medications in an off-label manner. 
The experts were asked whether the question was appropriate for the study, 
clear, in the correct sequence and complete. One expert (14%) did not provide 
answers for this question. 
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Six experts (86%) believed that question 2 was appropriate for this survey. 
Only one expert (14%) believed that question 2 was not clear. Because this 
response was received by only one expert, the question will remain unchanged. 
One respondent (14%) believed that the therapeutic areas should be 
presented in alphabetical order. Four experts (57%) suggested that additional 
categories should be added to the question. The suggestions included anti­
anxiety, anti-inflammatory, and a section for Other. One expert questioned the 
use of psychotropic, however, did not explain why so no changes are being 
made to this term. The suggested categories have not been added to the final 
version of the survey because only one expert made the suggestion for each 
therapeutic category. 
Question 3. The purpose of question 3 was to determine the age ranges 
treated by the pediatricians who complete the survey. The experts were asked 
whether the question was appropriate for the study, clear, and in the correct 
sequence. Two experts (29%) did not provide answers for this question. 
Five (71%) experts believed that this question was both appropriate and in 
the correct sequence for this survey. Only one expert (14%) believed that 
question 3 was not clear. Because this response was received by only one 
expert, the question will remain unchanged in the final version of the survey. 
Question 4. The purpose of question 4 was to determine the percent of 
medicines the pediatrician prescribed off-label in the last year. The experts were 
asked whether the question was appropriate for the study, clear, and in the 
correct sequence. Two experts did not provide answers for this question. 
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Five experts (71 %) believed that this question was both appropriate and in 
the correct sequence for this survey. Three experts (43%) believed that question 
2 was not clear. One expert asked whether this question needs to be qualified 
by age group as in question 3. One expert suggested to change the ranges for 
choices b-e from 1-25,25-50,50-75 and 75-100% to 1-5,5-10, 10-25, and >25% 
and another expert suggested to change the ranges to 1-25,26-50,51-75 and 
76-100%. 
Although none of these suggestions were made by more than one expert, 
the criteria established for making changes to the final version of the survey, the 
final version will be changed to reflect the latter suggestion. This change 
ensures that the answers are distinct from one another. 
Question 5. The purpose of question 5 was to determine the beliefs that 
pediatricians have about off-label prescribing. The experts were asked whether 
the question was appropriate for the study, clear, in the correct sequence and 
complete. One expert did not provide answers for this question. 
Five (71 %) experts believed that this question was appropriate for this 
survey. Because only one expert (14%) believed that changes should be made 
to the question, the question will remain unchanged. 
Six (86%) experts believed that the question was both clear and in the 
correct sequence. Two experts (29%) made suggestions for additional 
statements to be added to this question. The first suggestion was to add 
questions regarding the ethical implications of off-label prescribing (e.g. patient 
safety, informed consent) and the second was to add a statement saying "I 
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believe that patients should receive pharmacotherapy that presents the best 
outcome opportunity regardless of label use." Because the suggestions for this 
question were not received by two or more experts, meeting the previously 
defined criteria, this question will remain unchanged. 
Question 6. The purpose of question 6 was to determine in which state 
the pediatrician practices medicine. The experts were asked whether the 
question was appropriate for the study, clear, and in the correct sequence. Two 
experts (29%) did not provide answers for this question. The remaining experts 
(71 %) believed that this question was appropriate, clear and in the correct 
sequence for this survey. 
Question 7. The purpose of question 7 was to determine the country the 
pediatrician attended medical school, completed residency, completed fellowship 
and obtained board certification. The experts were asked whether the question 
was appropriate for the study, clear, in the correct sequence and complete. 
One expert (14%) did not provide answers for all questions; two experts 
(29%) did not provide responses for the last question. Six experts (86%) 
believed that the question was appropriate, clear and in the correct sequence for 
the survey. Two experts (29%) believed that additional options should be added 
to this question. One expert suggested that an option is added to allow for more 
than one residency. The other expert suggested to add an option to determine 
whether the pediatrician is a currently a licensed practitioner. Because both of 
these suggestions were made by only one expert each, the final version of the 
survey will remain unchanged. 
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Question 8. The purpose of question 8 was to determine whether the 
respondent is a general pediatrician, pediatric medical specialist or pediatric 
surgical specialist. The experts were asked whether the question was 
appropriate for the study, clear, in the correct sequence and complete. 
Two experts (29%) did not provide answers for the questions regarding 
appropriateness; the remainder of the experts (71 %) did believe that the question 
was appropriate. Two experts (29%) did not comment on the clarity of this 
question and four experts did believe that the question was clear. One expert 
believed that choices b & c should include a section for the respondents to write 
in their specific specialty. However, since this comment was received by only 
one expert, question 8 will remain unchanged. 
Four (57%) experts did not answer the question about sequence, while the 
remainder of the experts did believe that the question was in the correct 
sequence. None of the experts provided suggestions for additional options to 
this question. 
Question 9. The purpose of question 9 was to determine the number of 
years the respondent has been a practicing physician. The experts were asked 
whether the question was appropriate for the study, clear, and in the correct 
sequence. 
One expert (14%) did not provide a response for this question. Six experts 
(86%) believed that this question was appropriate and in the correct sequence. 
Two experts (29%) did not believe that this question was clear. One expert 
suggested that the words "post residency" be added to the question. Although 
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only one expert provided this comment, this phrase will be added to the final 
version of this survey to ensure that survey respondents all use the same 
definition for practicing physician. 
One expert questioned whether practice experience, specifically for 
pediatricians who have been practicing for 5-15 years, would skew the results of 
this study; however, this expert did not provide a suggestion for improvement. 
Because this response was received from only one expert, the final survey will 
remain unchanged. 
Question 10. The purpose of question 10 was to determine the working 
environment of the survey respondent. The experts were asked whether the 
question was appropriate for the study, clear, and in the correct sequence. 
Two experts (29%) did not provide an answer for the question about 
appropriateness. The remainder of the experts, however, did believe that this 
question was appropriate for this survey. One expert did not provide a response 
for the questions about clarity or sequence. Four experts (57%) believed that the 
question was clear; two experts (29%) provided suggestions for improving the 
clarity. 
Specifically, one expert believed that option b (group practice) should be 
separated into 3 categories - 2-10, 11-25 and greater than 25 doctors. The other 
expert suggested that an additional option be included for "other." Because 
neither suggestion was provided by two or more experts, this question will remain 
unchanged in the final version of the survey. 
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Question 11. The purpose of question 11 was to determine whether the 
pediatricians have any additional information about off-label prescribing to share 
with the researcher. The experts were asked whether the question was 
appropriate for the study, clear, and in the correct sequence. 
Two experts (29%) did not answer the question about appropriateness; 
three experts (43%) did not answer the questions about clarity and sequence. 
The remainder of the experts believed that this question was appropriate (71 %). 
clear (57%) and in the correct sequence (57%). Therefore, this question will 
remain unchanged. 
Additional suggestions. Experts were also provided the opportunity to 
make additional suggestions to improve the survey. One expert believed that an 
additional question could be added on the policy of off-label use in the given 
organization. The expert believed that the policies of the pediatrician's 
organization may have a larger impact on prescribing practices of the pediatrician 
than the individual pediatrician's attitudes and beliefs toward off-label prescribing. 
Because this comment was received by only one expert, no changes will be 
made to the final version of the survey based on this comment. 
An additional suggestion provided by an expert was that the research 
question uses the term influence, implying causality, and that this survey does 
not measure causality. No changes will be made to the final version of the 
survey based on this comment because it was received by only one expert. 
Results Summary 
97 
Only three changes were made to the survey based on the input from the 
experts. The first change was to the sequence of the answers in question 1. In 
the final version of the survey, the answers will be provided in order from most 
scientific to least scienti'flc, as suggested by two experts. 
Another change was made to improve the clarity of the answers for 
question 4. Instead of overlapping the choices (i.e. 1-25, 25-50, 50-75 and 75­
100), the final version of the survey will provide clearly distinct possibilities for the 
respondent (i.e. 1-25,26-50,51-75 and 76-100).· 
The wording of question 9 was changed to improve the clarity as well. The 
words "post residency" will be added to the final version of the survey to ensure 
that all respondents answer the question in the same manner. 
Appendix 1 contains the introduction letter and survey that was sent to the 
experts. Appendix 2 contains the final version of the survey, based on the 
responses from the experts. Overall, the survey did not change greatly from its 
initial format. The information that was changed between the two versions is 
indicated in italics. 
Conclusion 
The purpose of this paper was to describe the development and validation 
of a survey to be used to determine New Jersey pediatrician attitudes and beliefs 
towards of off-label prescribing. The survey was developed after a thorough 
review of published literature describing the issues associated with off-label 
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prescribing. Validation of the survey was performed by experts in healthcare and 
research to ensure that the survey was appropriate, clear and information was 
presented in the proper sequence. 
Survey validation allows the researcher to ensure that the survey will 
adequately capture the appropriate information necessary to conduct the 
research. Overall the experts believed that the survey was clear and appropriate 
and that the questions were presented in the correct sequence. Only minor 
changes were made to the final version of the survey and all were made to 
improve the clarity of the survey. All changes are highlighted in Appendix 2. 
99 
Appendix 1 
Survey Sent to Experts 
September 12, 2006 

Dear Healthcare Educator: 

I am a doctoral student at Seton Hall University in the School of Graduate 
Medical Education. Your name was provided to me as an expert in healthcare 
and research by Dr. Genevieve Pinto-Zipp, chair, Graduate Programs in Health 
Sciences. I would appreciate your input on the appropriateness, clarity and 
sequence of the questions in the attached survey. After the final version of the 
survey has been developed, a sample of pediatricians in New Jersey will be 
invited to participate in its completion, via email, over the internet. 
The purpose of the study is to determine the factors influencing 
pediatricians in prescribing medicines off-label. Off-label prescribing occurs 
when a physician prescribes a medicine in a manner where the dosage, age, 
indication and/or route of administration have not been approved by a health 
authority (not indicated on the medicine's label).1 While off-label prescribing is a 
I Conroy, S. (2002). Unlicensed and off-label drug use: issues and recommendations. Pediatric Drugs, 4 
(6),353-359. 
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legal and widely accepted practice, up to 33% of children in the community, up to 
60% of children in a pediatric hospital ward and up to 63% of children in a 
neonatal hospital ward receive medicines off-label. 2 
Please provide your responses and comments in the grey box below each 
question on the enclosed survey. Please also use the following definitions when 
providing your feedback: 
Appropriate: The survey question and answers are suitable for this study. 
Clear: The survey question and answers are easy to understand. 
Sequence: The survey questions and answers are presented in a logical 
order. 
Your thoughtful response to this request should take no longer than 20 
minutes. Please return your comments in the enclosed envelope, addressed to 
Joann DeBerto, secretary, Seton Hall Graduate Programs in Health Science, no 
later than September 26, 2006. If you would like to complete your review 
electronically, please email your request to me at herbstel@shu.edu. Upon 
completion of the data analysis, the final results of the study will be provided to 
you. 
Sincerely, 

Elizabeth G. Evola 

2 Pandolfini, C. & Bonati, M. (2005). A literature review on off-label drug use in children. European 
Journal ofPediatrics, 164,552-558. 
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Survey Instructions 
By completing this survey, you consent for the researcher to use your 
answers for research purposes. Please use the following definitions when 
responding to the survey questions: 
Off-label: A medicine prescribed in a manner where the dosage, age, 

indication and/or route ofadministration are not indicated on the medicine's 

label (have not been approved by a health authority).3 

Regularly: I perform this activity greater than 75% of the time. 

Often: I perform this activity greater than half but less than 75% of the time. 

Sometimes: I perform this activity greater than 25% but less than half of the 

time. 

Rarely: I perform this activity less than 25% of the time. 

Never: I do not perform this activity. 

Are these instructions appropriate for this survey, yes or no? 
If no, what are your suggestions for improvement? 
Are these instructions clear, yes or no? 
If no, what are your suggestions for improvement? 
! 
Survey Questions 
J Conroy, S. (2002). Lnlicensed and otT-label drug use: issues and recommendations. Pediatric Drugs, 4 
(6),353-359. 
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1) I use the following to determine whether or not to prescribe medicine to my 
patients: 
! 
i 
i 
Regularly Often Sometimes Rarely Never 
Reference Manuals (e.g. 
Physicians Desk Reference 
(PDR» 
Patient / guardian suggestion 
Patient / guardian request 
Patient insurance company 
My previous experience with 
i the medicine 
My group/ hospital! facility/ 
office's experience with the 
medicine 
The medicine's label 
(prescribing information) i 
Published research 
Unpublished research 
Peer recommendations 
Information from 
pharmaceutical representative 
Is Question #1 appropriate for this survey, yes or no? 
If no, what are your suggestions for improvement? 
Is Question #1 clear, yes or no? 
If no, what are your suggestions for improvement? 
Is Question #1 in the correct sequence, yes or no? 
If no, what are your suggestions for improvement? 
Are there any other references that should be included in the list in Question #1, 
yes or no? 
If yes, name them here. 
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2) Once per month, at minimum, I prescribe medicines in the following 
categories in an off-label manner. 
I 
I 
Regularly Often Sometimes Rarely Never 
Dermatologics 
Otologics 
Psycholeptic and 
psychoanaleptics 
Analgesics 
Rhinologicals 
Antihistamines 
Expectorants and anti­
tussive agents 
Anti-epileptics 
Anti-asthmatics 
Antibiotics 
Insulin 
Is Question #2 appropriate for this survey, yes or no? 
If no, what are your suggestions for improvement? 
Is Question #2 clear, yes or no? 
If no what are your suggestions for improvement? 
Is Question #2 in the correct sequence, yes or no? 
If no, what are your suggestions for improvement? 
Are there any other medicinal categories that should be included in the list in 
Question #2, yes or no? 
If yes, name them here. 
3) Once per month, at minimum, I prescribe medicines to patients in the 
following age ranges in an off-label manner. 
Never 
Less than 1 ear old 
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I 
1-5 years old 
5-12 years old 
13-18 years old 
Greater than 18 years 
old 
Is Question #3 appropriate for this survey, yes or no? 
':"If no, what are your suggestions for improvement? . 
Is Question #3 clear, yes or no? 

If no, what are your suggestions for improvement? 

.. 
Is Question #3 in the correct sequence, yes or no? 

If no, what are your suggestions for improvement? 

4) In the last year, what is the percent of medicines that you prescribed off­
label? 
a) None 
b) 1- 25 % 
c) 25 - 50% 
d) 50 - 75% 
e) 75 - 100% 
Is Question #4 appropriate for this survey, yes or no? 
If no, what are your suggestions for improvement? 
Is Question #4 clear, yes or no? 
If no, what are your suggestions for improvement? 
Is Question #4 in the correct sequence, yes or no? 
If no, what are your suggestions for improvement? 
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5) Although the practice of medicine allows for physicians to prescribe 
medicines off-label, please complete the following section with regard to your 
beliefs about off-label prescribing. 
Strongly 
Agree 
Agree Neutral Disagree Strongly 
Disagree 
I do not 
prescribe 
medicines 
off-label. 
When I 
prescribe a 
medicine off-
label, I am 
concerned 
about the legal 
liabilities. 
When I 
prescribe a 
medicine off-
label, I am 
concerned that 
patients (or 
their guardians) 
will complain. 
I believe that 
physicians 
should not be 
legally allowed 
to prescribe 
medicines off-
label. 
Is Question #5 appropriate for this survey, yes or no? 
If no, what are your suggestions for improvement? 
Is Question #5 clear, yes or no? 
If no, what are your suggestions for improvement? 
Is Question #5 in the correct sequence, yes or no? 
If no, what are your suggestions for improvement? 
Are there any other options that should be included in the list in Question #5, yes 
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If no, what are our su 
6) In what state do you practice medicine? 
a) New Jersey 
b) Other _______ 
Is Question #6 appropriate for this survey, yes or no? 
If no, what are your suggestions for improvement? 
Is Question #6 clear, yes or no? 
If no, what are your suggestions for improvement? 
Is Question #6 in the correct sequence, yes or no? 
If no, what are your suggestions for improvement? 
7) In which country did you: 
United States If outside United 
States, enter 
name of 
country. 
Not applicable 
Attend Medical 
School? 
Complete 
Residency? 
Complete 
Fe"owship? 
Obtain Board 
Certification? 
Is Question #7 a ro riate for this surve , es or no? 
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Are there any other options that should be included in the list in Question #7, yes 
or no? . . 
If es, nam~them .here. 
8) Are you a: (please choose only one answer) 
a.) Pediatrician 
b.) Pediatric medical subspecialist 
c.) Pediatric surgical specialist 
Is Question #8 appropriate for this survey, yes or no? 
If no, what are your suggestions for improvement? 
Is Question #8 clear, yes or no? 
If no, what are your suggestions for improvement? 
Is Question #8 in the correct sequence, yes or no? 
If no, what are your suggestions for improvement? 
Are there any other options that should be included in the list in Question #8, yes 
•or no? 
i If yes, name them here. 
9) How many years have you been a practicing physician? 
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a. Less than 5 years 
b. 5-15 years 
c. 15-25 years 
d. greater than 25 years 
Is Question #9 appropriate for this survey, yes or no? 
If no, what are your suggestions for improvement? 
Is Question #9 clear, yes or no? 
If no, what are your suggestions for improvement? 
Is Question #9 in the correct sequence, yes or no? 
If no, what are your suggestions for improvement? 
10) What type of environment do you currently work in? (please choose all that 
apply) 
a.) Solo practice 

b.) Group practice 

c.) Hospital based practice - non-teaching 

d.) Hospital based practice - teaching 

Is Question #10 appropriate for this survey, yes or no? 
If no, what are your suggestions for improvement? 
Is Question #10 clear, yes or no? 
If no, what are your suggestions for improvement? 
Is Question #10 in the correct sequence, yes or no? 
If no, what are your suggestions for improvement? 
•••••••••••• 
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11) Please provide any additional information about your off-label prescribing 
practices for the researcher to consider. 
Is Question#11 appropriate for this survey. yes or no? ;; . ,:,,' .~,: 
If no, what are your suggestions for improvement?.k· ,'"". c . 
.F 
; .. : 
.... 
·t. 
. .......
Is Question #11 clear, yes or no? 
".
I If no, what are your suggestions for improvement? ,~ 
•....... . 

I 
 :'. 
..... 
." 
Is Question #11 in the correct sequence, yes or no?1 
I If no, what are your suggestions for improvement? 
1 
i 
1 ~ 
1 

1 

In thespacebelow. please provide al1~additionalsugges\ions for this surveyr:, 
Thank you for your time in completihg"this survey.;; .•. . 
Please send any additional comments to me using the enclosed envelope 
or email me at herbstel@shu.edu. 
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Appendix 2 
Final Survey 
Survey Instructions 
By completing this survey, you consent for the researcher to use your 
answers for research purposes. 
Please use the following definitions when responding to the survey 
questions: 
Off-label: A medicine prescribed in a manner where the dosage, age, 

indication and/or route of administration are not indicated on the medicine's 

label (have not been approved by a health authority).4 

Regularly: I perform this activity greater than 75% of the time. 

Often: I perform this activity greater than half but less than 75% of the time. 

Sometimes: I perform this activity greater than 25% but less than half of the 

time. 

4 Conroy, s. (2002). Unlicensed and off-label drug use: issues and recommendations. Pediatric Dnlgs, 4 
(6),353-359. 
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Rarely: I perform this activity less than 25% of the time. 
Never: I do not perform this activity. 
Regularly Often Sometimes Rarely Never i 
Reference Manuals (e.g. 
Physicians Desk Reference 
(PDR), etc.) 
Published research 
Unpublished research 
The medicine's label 
(prescribing information) 
My previous experience with 
the medicine 
My group/ hospital/ facility/ 
office's experience with the 
medicine 
Peer recommendations 
Information from 
pharmaceutical representative 
Patient insurance company 
Patient / guardian suggestion 
• Patient / guardian request 
Survey Questions 
1) I use the following to determine whether or not to prescribe medicine to my 
patients: 
I 
I 
2) Once per month, at minimum, I prescribe medicines in the following 
categories in an off-label manner. 
Regularly Often Sometimes Rarely Never 
Analgesics 
Anti-asthmatics 
I Anti-epileptics 
Antibiotics 
Antihistamines 
Dermatologics 
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Expectorants and anti­
tussive agents 
Insulin 
Otologics 
Psycholeptic and 
psychoanaleptics 
Rhinologicals 
3) Once per month, at minimum, I prescribe medicines to patients in the 
following age ranges in an off-label manner. 
Regularly Often Sometimes Rarely Never 
Less than 1 year old 
1-5 years old 
5-12 years old 
13-18 years old 
Greater than 18 years 
old 
4) 	In the last year, what is the percent of medicines that you prescribed off­
label? 
a) None 
b) 1- 25 % 
c) 26-50% 
d) 51 - 75% 
e) 76 100% 
5) Although the practice of medicine allows for physicians to prescribe 
medicines off-label, please complete the following section with regard to your 
beliefs about off-label prescribing. 
Strongly 
Agree 
Agree Neutral Disagree Strongly 
Disagree 
I do not 
prescribe 
medicines 
off-label. 
When I 
prescribe a 
medicine off-
label, I am 
• 
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concerned 
about the legal 
liabilities. 
When I 
prescribe a 
medicine off­
label, I am 
concerned that 
patients (or 
their guardians) 
will complain. 
I believe that 
physicians 
should not be 
legally allowed 
to prescribe 
medicines off­
label. 
6) 	 In what state do you practice medicine? 
a) New Jersey 
b) Other _______ 
7) 	 In which country did you: 
United States If outside United 
States, enter 
name of 
country. 
Not applicable 
Attend Medical 
School? 
Complete First 
Residency? 
Complete 
Fellowship? 
Obtain Board 
Certification? 
8} Are you a: (please choose only one answer) 
a.) Pediatrician 
b.) Pediatric medical subspecialist 
c.) Pediatric surgical specialist 
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9) How many years have you been a practicing physician (post residency)? 
a.) Less than 5 years 
b.) 5-15 years 
c.) 15-25 years 
d.) Greater than 25 years 
10) What type of environment do you currently work in? (please choose all that 
apply) 
a.) Solo practice 

b.) Hospital based practice - non-teaching 

c.) Hospital based practice - teaching 

11) Please provide any additional information about your off-label prescribing 
practices for the researcher to consider. 
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Appendix B 
Final Survey 
Survey Instructions 
By completing this survey, you consent for the researcher to use your answers 

for research purposes. 

Please use the following definitions when responding to the survey questions: 

Off-label: A medicine prescribed in a manner where the dosage, age, indication 

and/or route of administration are not indicated on the medicine's label (have not 

been approved by a health authority).5 

Regularly: I perform this activity greater than 75% of the time. 

Often: I perform this activity greater than half but less than 75% of the time. 

Sometimes: I perform this activity greater than 25% but less than half of the 

time. 

Rarely: I perform this activity less than 25% of the time. 

5 Conroy, S. (2002). Unlicensed and off-label drug use: issues and recommendations. Pediatric Drugs. 4 
(6),353-359. 
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Never: I do not perform this activity. 
Strongly Agree: I agree most or all of the time. 

Agree: I agree some of the time. 

Neutral: I neither agree nor disagree. 

Disagree: I disagree some of the time. 

Strongly Disagree: I disagree most or all of the time. 

Survey Questions 
1. 	 I use the following to determine whether or not to prescribe medicine to my 
patients: 
Regularly Often Sometimes Rarely Never 
The medicine's label 
(prescribing information) 
Published, peer-reviewed 
research 
Reference Manuals (e.g. 
Physicians Desk Reference 
(PDR), etc.) 
Published, not peer-reviewed 
research 
Unpublished research 
My previous experience with 
the medicine 
My group! hospital! facility! 
office's experience with the 
medicine 
Peer recommendations 
Information from 
pharmaceutical represent 
Patient insurance company 
Patient! guardian suggestion 
Patient! guardian request 
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2. Once per month, at minimum, I prescribe medicines in the following 
categories in an off-label manner. 
Regularly Often Sometimes Rarely Never 
Analgesics 
Anti-asthmatics 
Anti-epileptics 
Antibiotics 
Antihistamines 
Dermatologics 
Expectorants and anti-tussive 
agents 
Insulin 
Otologics 
Psycholeptic and 
l??ychoa nal e ptics 
Rhinologicals 
3. Once per month, at minimum, I prescribe medicines to patients in the 
following age ranges in an off-label manner. 
Regularly Often Sometimes Rarely Never 
Less than 1 year old 
1-5 years old 
5-12 years old 
13-18 years old 
Greater than 18 years 
old 
4. 	 In the last year, what is the percent of medicines that you prescribed off-
label? 
• 	 None 
• 	 25 % 
• 	 26 - 50% 
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• 	 51 - 75% 
• 	 76 - 100% 
5. 	 Although the practice of medicine allows for physicians to prescribe 
medicines off-label, please complete the following section with regard to your 
beliefs about off-label prescribing. 
Strongly 
Agree 
Agree Neutral Disagree Strongly 
Disagree 
I do not 
prescribe 
medicines 
off-label. 
When I 
prescribe a 
medicine off-
label, I am 
concerned 
about the legal 
liabilities. 
When I 
prescribe a 
medicine off-
label, I am 
concerned that 
patients (or 
their guardians) 
will complain. 
I bel ieve that 
physicians 
should not be 
legally allowed 
to prescribe 
medicines off-
label. 
6. 	 In what state do you practice medicine? 
• 	 New Jersey 
-------
1 
I 
I 
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~ 
• Tennessee 
I 
• Other! ------­
! 
7. In which country did you: 
United States If outside United 
States, enter name 
of country. 
Not applicable 
Attend Medical School? 
Complete First 
Residency? 
Complete Fellowship? 
Obtain Board 
Certification? 
8. Are you a: (please choose only one answer) 
• Pediatrician 
• Pediatric medical subspecialist 
• Pediatric surgical specialist 
• Other 
9. How many years have you been a practicing physician (post residency)? 
• Less than 5 years 
• 5-15 years 
• 15-25 years 
• Greater than 25 years 
• I am a resident 
• None of the above 
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10. 	 What type of environment do you currently work in? (please choose all that 
apply) 
• 	 Solo practice 
• 	 Group non-hospital based practice 
• 	 Non-teaching hospital based practice 
• 	 Teaching hospital based practice 
11. Please provide any additional information about your off-label prescribing 
practices for the researcher to consider. 
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November 4, 2008 
Dear Ms. Catherine M. Fenner: 
I am a doctoral candidate at Seton Hall University, School of Health and 
Medical Sciences and my dissertation topic is pediatric off-label prescribing 
practices. 
The purpose of my dissertation research is to determine pediatrician off-
label prescribing practices. Off-label prescribing occurs when a physician 
prescribes a drug in a manner where the dosage, age, indication and/or route of 
administration are not approved by a health authority (not indicated on the drug's 
label) (Conroy, 2002). 
This confirms our conversation on <<date», that you will send an email 
invitation to complete an online survey, which I created and validated (Appendix 
1), to the membership of the American Academy of PediatriCS, Tennessee 
Chapter (TNAAP). The survey will be placed on wwwJormsite.com, a survey-
hosting website, which allows the members of your organization to complete it 
online and anonymously. The completion of the survey should take no longer 
than 10 minutes and will be available on the 1Nebsite for two months. 
I will send you the initial invitation (Appendix 2) for your membership once 
the Seton Hall University Institutional Review Board (lRB) has approved my 
study. In addition, two weeks and four weeks after the initial invitation is sent, I 
will provide you with a follow-up invitation (Appendix 3) for all members of 
TNAAP who received the initial email. 
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As a token of my appreciation, please contact me at the email address 
below and I would be pleased to provide the results of my study to you or your 
membership. when available. Thank you, in advance, for your assistance with 
this study. 
Sincerely. 
Elizabeth G. Evola 
ElizabethEvola@yahoo.com 
8658249433 
rf you concur with this request. please sign and date this letter and return the 
original copy to me in the envelope provided. Again. thank you for your interest 
in the project. 
J ' 
Catherine M. Fenner, Execu1ive Director Date 
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Appendix D 
NJAAP Approval 
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November 12. 2008 
Dear Dr. Segarra: 
I am a doctoral candidate at Seton Hall Uni rsity, School of Health and 
Medical Sciences and my dissertation topic is 
practices. 
The purpose of my dissert.Qtion research Is 0 d.rmine pediatrician off· 
label prescribing practices. Dff-label prescribing ccurs when a physician 
prescribes a drug in a manner where the dosage, e, indicutfon and/or route of 
administration are not approved by a health autho "ty (no1lndicated on the drug's 
label) (Conroy. 2002). 
This confirms our conversation on Novem r 12. 2008. that you will send 
an email Invitation to completa an online survey, Ich I created and validated 
(Appendix 1). Co the membership of the New Jers y Chapter of the American 
Academy of Pediatrics (AAPINJ). The survey Will e placed on 
www.formslte.com. II survey-hosting website. whl allows the members of your 
organization to complete it online and anonymous y. The completion of the 
survey should take no longer than 10 minutes an will be available on the 
website for two monti'll. 
I will send you the initial Invitation (Appeodi 2) for your membership once 
the Seton Hall University Institutional Review Boa (IRS) has approved my 
study. In addition, two Meks and four weeks aft 
will provide you with a follow-up invitation (Appen ix 3) for all members of 
TNAAP who received the initial email. 
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As 8 token of my appreciation, please con 
below and I would be pleased to provide the rnu 
membership. when available. Thank you, in adYB 
this study. 
me at the email address 
of my study to you or your 
ee, for your assistance with 
Sincerely, 
Elizabeth G. Evola 
ElizabethEvola@yahoo.com 
865824 9433 
If you concur with this request. please sign and d te this letter and return it to me. 
Again, thank you for your interest in the proj~. 
j~c4~~. Micha::Seg~ 
AAP/NJ President 
November 13. 2008 
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Seton Hall University IRB Approval 
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REQUEST FOR APPROVAL OF RESEARCH, DEMONSTRATION OR 
RELATED ACTIVITIES INVOLVING HUMAN SUBJECTS 
All material must be typed. 
PROJECT TITLE: Off-label Prescribing: Pediatrician Beliefs and E;.>sP~[ifl.QqL-
CERTIFICATION STATEMENT: 
In making this application, I(we) certify that I(we) havG read and understand the University's policies and procedures 
governing research, development, and related activities involving human subjects. I (we) shall comply with the letter 
and spirit of those policies. l(we) further acknowledge my(our) obligation to (1) obtain written approval of significant 
deviations from the originally-approved protocol BEFORE making those deviations, and (2) report immediately all 
adverse effects of the study on Ihe subjects 10 the Director of the Institutional Review Board, Seton Hall University, 
§'outh Orange, NJ 07079. 
(;;- li.f "L.() ! ):1'"f'i J ( ... , ..' J~ ;~;i~~ ~~~.~ .~ >", ,.. f, 
"'Please print or type out names of aU researchers below signature. 
Use separate sheet of paper, if necessary... 
My Signature indicates that I have reviewed the attached materials and consider them to meet IRB standards. 
DA~/c27--
"Please print or type out name below signature" 
The request for approval submitted by the above resi2'Lcher(s) wss considered by the IRB for Research 
Involving Human Subjects Research.aHl're I ...tv I ~ 2.oq ~
/ 
The appticalig;;! was approved _~t approved _._ by the Committee. Special conditions were __ 
were not ./ set by tlle IRB. (Any special condilions are described on the reverse side.) 
~f f. til .0_,
DIRECTOR, rr ......... --­
SETON HALL UNIVERStTY tNSTI TIONI\L 
REVIEW f30AI\O FOR HUMAN SUBJECTS RESE.~RCII 
Seton Hall University 
312005 
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Appendix F 
Initial Survey Invitation 
Dear Pediatrician: 
I am a Doctoral Candidate at Seton Hall University in the School of Health 
and Medical Sciences and I am studying pediatric off-label prescribing practices. 
You are receiving this email via the email distribution of the New Jersey or 
Tennessee chapter of the American Academy of Pediatrics. 
The purpose of the study is to determine pediatrician off-label prescribing 
practices. Off-label prescribing occurs when a physician prescribes a drug in a 
manner where the dosage, age, indication and/or route of administration have 
not been approved by a health authority (not indicated on the drug's label) 
(Conroy, 2002). 
The survey has been designed so that you can complete it anonymously 
via the following link: <link will be included here>. It should take no longer than 
10 minutes of your time. 
Your assistance is greatly appreciated and your response can be provided 
anonymously and will be kept confidential. As a token of my appreciation, please 
contact me at the email address below and I will provide the results of my study 
to you, when available. 
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Sincerely, 
Elizabeth G. Evola 
ElizabethEvola@yahoo.com 
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Appendix G 
Two week follow-up Survey Invitation 
Dear Pediatrician: 
This email is a follow-up to an email that you received two weeks ago. 
am a Doctoral Candidate at Seton Hall University in the School of Health and 
Medical Sciences and I am studying pediatric off-label prescribing practices. You 
are receiving this email via the email distribution of the New Jersey or Tennessee 
chapter of the American Academy of Pediatrics. 
If you have already responded to my survey, I thank you very much for 
your time. If not, I would greatly appreciate it if you could assist me in my 
research by completing the short survey. As I explained in my previous email, I 
am looking to determine the attitudes and beliefs of pediatricians towards off­
label prescribing, a practice that occurs when a physician prescribes a medicine 
in a manner that has not been approved by a health authority (i.e. not indicated 
on the drug's label) (Conroy, 2002). 
The survey allows you to complete it anonymously via the following link: 
<link will be included here>. It should take no longer than 10 minutes of your 
time. 
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Your assistance is greatly appreciated. If you have already responded to 
I my survey, again, I thank you very much for your time. 
Sincerely,j 
i Elizabeth G. Evola 
ElizabethEvola@yahoo.com 
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Appendix H 
Four week follow-up Survey Invitation 
Dear Pediatrician: 
This email is a follow-up to an email that you received about one month 
ago. I am a Doctoral Candidate at Seton Hall University in the School of Health 
and Medical Sciences and I am studying pediatric off-label prescribing practices. 
You are receiving this email via the email distribution of the New Jersey or 
Tennessee chapter of the American Academy of Pediatrics. 
If you have already responded to my survey, I thank you very much for 
your time. If not, I would greatly appreciate it if you could assist me in my 
research by completing the short survey. As I explained in my previous email, I 
am looking to determine the attitudes and beliefs of pediatricians towards off­
label prescribing, a practice that occurs when a physician prescribes a medicine 
in a manner that has not been approved by a health authority (i.e. not indicated 
on the drug's label) (Conroy, 2002). 
The survey allows you to complete it anonymously via the following link: 
<link will be included here>. It should take no longer than 10 minutes of your 
time. 
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Your assistance is greatly appreciated. If you have already responded to 
my survey, again, I thank you very much for your time. 
Sincerely, 
Elizabeth G. Evola 
ElizabethEvola@yahoo.com 
